



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/770,726	02/04/2004	Eugene Brown	WYE-032	6144
54623 7590 08/22/2007 KIRKPATRICK & LOCKHART PRESTON GATES ELLIS LLP (FORMERLY KIRKPATRICK&LOCKHART NICHOLSON GRAHAM) STATE STREET FINANCIAL CENTER ONE LINCOLN STREET BOSTON, MA 02111-2950			EXAMINER DUFFY, BRADLEY	
			ART UNIT 1643	PAPER NUMBER
			MAIL DATE 08/22/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/770,726

Applicant(s)

BROWN ET AL.

Examiner

Brad Duffy

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 May 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,5-7 and 26-30 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,5-7 and 26-30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☒ Other: Exhibit A, B, C and D.

DETAILED ACTION

1. The amendment filed May 21, 2007, is acknowledged and has been entered. Claims 21-25 have been cancelled. Claims 1, 5-7 have been amended. Claims 26-30 have been newly added.
2. Claims 1, 5-7 and 26-30 are pending in the application and are under examination.
3. The following Office action contains **NEW GROUNDS** of rejection necessitated by amendment.

Priority

4. Applicant's claim under 35 USC §§ 119 and/or 120 for benefit of the earlier filing date of the 60/444,637, filed February 4, 2003, is acknowledged.

However, claims 1, 5-7 and 26-29 do not properly benefit under 35 U.S.C. §§ 119 and/or 120 by the earlier filing dates of the priority documents claimed, since those claims are rejected under 35 U.S.C. § 112, first paragraph, as lacking a sufficiently enabling disclosure.

To receive benefit of the earlier filing date under 35 USC §§ 119 and/or 120, the later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application); the disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

Accordingly, the effective filing date of claims 1, 5-7 and 26-29¹ is deemed the filing date of the instant application, namely February 4, 2004.

Grounds of Objection and Rejection Withdrawn

5. Unless specifically reiterated below, Applicant's amendment and/or arguments filed May 21, 2007, have obviated or rendered moot the grounds of objection and rejection set forth in the previous Office action mailed February 20, 2007.

Grounds of Objection Maintained

6. The objection to the specification because the use of improperly demarcated trademarks is maintained. Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner that might adversely affect their validity as trademarks. See MPEP § 608.01(v).

Although it appears that Applicant has made a *bona fide* attempt to resolve this issue by appropriately amending the specification, an additional example of an improperly demarcated trademark appearing in the specification is noted, namely Taxol™; see, e.g., paragraph [0101] of the published application.

Again, appropriate correction is required. Each letter of a trademark should be capitalized or otherwise the trademark should be demarcated with the appropriate symbol indicating its proprietary nature (e.g., ™, ®), and accompanied by generic terminology. Applicants may identify trademarks using the "Trademark" search engine under "USPTO Search Collections" on the Internet at <http://www.uspto.gov/web/menu/search.html>.

Grounds of Rejection Maintained

¹ Note: Claim 30 is indefinite, as noted below, and cannot be examined for compliance with the requirements set forth under 35 U.S.C. §§ 112, first paragraph, 102, and 103.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. The rejection of claims 1, 5-7 and 26-29 under 35 U.S.C. 112, first paragraph, because the specification, **while being enabling for using** a method of detecting colon adenocarcinoma markers comprising detecting an expression profile of at least one nucleic acid in a colon cancer tissue from a human subject, wherein said at least one nucleic acid is selected from the group of SEQ ID NO:26, SEQ ID NO:1, and SEQ ID NO: 12, wherein said at least one nucleic acid is overexpressed compared to a normal colon tissue reference control, **and while being enabling for using** a method of detecting lung adenocarcinoma markers comprising detecting an expression profile of at least one nucleic acid in a lung cancer tissue from a human subject, wherein said at least one nucleic acid is selected from the group of SEQ ID NO:26, SEQ ID NO:1, and SEQ ID NO: 12, wherein said at least one nucleic acid is overexpressed compared to a normal lung tissue reference control, **and while being enabling for using** any process encompassed by the claims, which has been described by the prior art, **does not reasonably provide enablement for using** the claimed processes, is maintained. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

At page 8 of the amendment filed May 21, 2007, Applicant has traversed this ground of rejection.

Applicant's arguments traversing the ground of rejection set forth in the preceding Office action have been carefully considered but not found persuasive to obviate this rejection.

M.P.E.P. § 2164.01 states:

The standard for determining whether the specification meets the enablement requirement was cast in the Supreme Court decision of *Mineral Separation v. Hyde*, 242 U.S. 261, 270 (1916) which

Art Unit: 1643

postured the question: is the experimentation needed to practice the invention undue or unreasonable? That standard is still the one to be applied. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). Accordingly, even though the statute does not use the term "undue experimentation," it has been interpreted to require that the claimed invention be enabled so that any person skilled in the art can make and use the invention without undue experimentation. *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue". These factors, which have been outlined in the Federal Circuit decision of *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), include, but are not limited to, the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability or unpredictability of the art, the breadth of the claims, and the quantity of experimentation which would be required in order to practice the invention as claimed. See also *Ex parte Forman*, 230 USPQ 546 (BPAI 1986).

The amount of guidance, direction, and exemplification disclosed in the specification, as filed, would not be sufficient to enable the skilled artisan to use the claimed invention at the time the application was filed without undue and/or unreasonable experimentation.

The present claims are directed to methods of detecting an expression profile of at least one nucleic acid in a colon or lung cancer tissue from a human subject, wherein said at least one nucleic acid comprises a sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26; comparing said expression profile to a normal tissue reference expression profile of said at least one nucleic acid; and determining whether the nucleic acid is overexpressed compared to the normal tissue reference expression profile, thereby to detect a marker of the colon or lung cancer.

Notably, while Applicant's response at page 8 filed May 21, 2007, does provide evidence that the specification also teaches the overexpression of each of the mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 in lung

cancer tissue, as compared to a normal lung tissue reference expression profile, as well as the overexpression of each of the mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 in colon cancer tissue, as compared to a colon tissue reference expression profile (see page 8, 2nd paragraph of the response filed May 21, 2007 and Table 6A of the specification), it is noted that the claims are not limited to comparing the claimed cancer tissue expression profile to a corresponding normal lung or colon tissue profile, respectively; accordingly, the claims are directed to comparing the colon or lung cancer expression profile to any normal tissue reference profile and one of skill in the art would be subject to undue experimentation to use methods of detecting a colon or lung cancer marker, wherein the expression profile of the mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 in a colon cancer tissue or a lung cancer tissue are not compared to a corresponding normal colon tissue reference profile or a corresponding normal lung tissue reference profile, respectively.

Notably, the specification discloses the following about the cancer markers of the invention:

The present invention pertains to the use of the CPKGs listed in Table 1, the transcribed polynucleotides (CPKPN), and the encoded polypeptides (CPKPP) as markers for cancer. Moreover, the use of expression profiles of these genes can indicate the presence of a risk of cancer. (see page 31).

The present invention provides compositions and methods for the diagnosis, prevention, or treatment of numerous cancers. The present invention also provides methods for the identification of novel therapeutic agents for treating cancers. In addition, the present invention provides animal models useful for studying the pathogenesis of cancers. The present invention is based on the discovery of cancer genes that are overexpressed in at least two types of cancer tissues as compared to corresponding cancer-free tissues. In many embodiments, the cancer genes are overexpressed in colon cancer, lung cancer, breast cancer, or prostate cancer tissues, as compared to the corresponding cancer-free tissues. (see page 9).

Thus, for example, while the specification enables the skilled artisan to use processes to detect overexpressed mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 as colon cancer markers by comparing a colon cancer expression profile of the mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 with a expression profile of said mRNAs in a corresponding cancer-free colon tissue, it does not reasonably enable the use of the claimed processes to detect colon or lung cancer markers in which the comparison made is to any "normal tissue reference expression profile", but not necessarily those of normal (i.e., non-cancerous) colon and lung tissues, respectively, because the specification does not teach other normal tissue expression reference profiles that could be used to detect the claimed mRNAs as a "marker" of colon cancer. Furthermore, it is submitted that the skilled artisan cannot predict whether any such comparison to a "normal tissue reference expression profile", where the tissue is not colon or lung tissue, will identify a marker of colon or lung cancer, but in most cases it is expected that it would not.

Thus, contrary to Applicant's argument, the amendment to claim 1 has not obviated the ground of rejection set forth in the preceding Office action because the amendment does not require that the expression profile of the colon cancer tissue be compared to a normal colon tissue reference expression profile as set forth in the preceding Office action. Similarly, while Applicant has provided evidence that the specification would enable detecting the expression profile of mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 in a lung cancer tissue and comparing said expression profile to a normal lung tissue reference expression profile to detect lung cancer markers as the mRNAs comprising the sequence of SEQ ID NO: 1, SEQ ID NO:12, and SEQ ID NO:26 are also overexpressed in lung cancer, the amendment to claim 1 has not enabled using these lung cancer markers as the lung cancer tissue expression profile can be compared to any normal tissue expression profile and one of skill in the art would be subject to undue experimentation to use such methods.

In conclusion, upon careful consideration of the factors used to determine

whether undue experimentation is required, in accordance with the Federal Circuit decision of *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988), the amount of guidance, direction, and exemplification disclosed in the specification, as filed, is not deemed sufficient to have enable the skilled artisan to use the claimed invention at the time the application was filed without undue and/or unreasonable experimentation.

New Grounds of Objection

9. Claim 7 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

In this case, the method of claim 1 is practiced by detecting an expression profile of at least one nucleic acid in a colon cancer tissue, as opposed to a lung cancer tissue, from a human subject having lung cancer in accordance with claim 7, it is unclear how, or whether the limitation recited in claim 7 further limits the subject matter of claim 1.

Must the subject have both colon and lung cancers?

10. Claim 26 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

In this case, the method of claim 1 is practiced by detecting an expression profile of at least one nucleic acid in a colon cancer tissue, as opposed to a lung cancer tissue, from a human subject having lung cancer in accordance with claim 26, it is unclear how, or whether the limitation recited in claim 26 further limits the subject matter of claim 1.

Must the subject have both colon and lung cancers?

New Grounds of Rejection

Claim Rejections - 35 USC § 112

11. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

12. Claim 30 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 30 is indefinite in the recitation of "wherein the sequence is SEQ ID NO:31". This limitation lacks antecedent basis, as claim 1 only refers to "a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO12 and SEQ ID NO:26".

Accordingly, the claim fails to delineate the subject matter that Applicant regards as the invention with the requisite degree of clarity and particularity to permit the skilled artisan to know or determine infringing and non-infringing subject matter and thereby satisfy the requirement set forth under 35 U.S.C. § 112, second paragraph.

Claim Rejections - 35 USC § 102

13. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

14. Claims 1, 7, 26 and 29 are rejected under 35 U.S.C. 102(a) as being anticipated by WO 03/025138 A2 (Afar et al, published March 2003).

The claims are herein drawn to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:26 in a colon cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:26 from normal colon tissue to determine whether

said nucleic acid is overexpressed in the cancer tissue or to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:26 in a lung cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:26 from normal lung tissue to determine whether said nucleic acid is overexpressed in the cancer tissue.

Afar et al teach methods of detecting an expression profile of an mRNA comprising a nucleotide sequence that is 100% identical to the instantly claimed SEQ ID NO:26 in colon cancer tissues², and comparing said expression profile to the expression profile of an mRNA from corresponding normal colon tissue to determine whether said nucleic acid is overexpressed in the cancer tissue. Afar et al also teach methods of detecting an expression profile of an mRNA comprising a nucleotide sequence that is 100% identical to the instantly claimed SEQ ID NO:26 in lung cancer tissues, and comparing said expression profile to the expression profile of an mRNA from corresponding normal lung tissue to determine whether said nucleic acid is overexpressed in the cancer tissue; see entire document (e.g., SEQ ID NO:27; page 6, lines 4-27; page 23, line 13 through page 25, line 24; page 37, line 26 through page 38, line 12; and page 52, line 16 through page 53, line 32).

Thus, Afar et al anticipate these claims.

Claim Rejections - 35 USC § 103

15. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

² See the alignment of these sequences attached here as Exhibit A.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

16. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

17. Claims 1, 5, and 6 are rejected under 35 U.S.C. 103(a) as being anticipated by WO 03/025138 A2 (Afar et al, published 2003).

Claims 1, 5, and 6 are directed to the method of claim 1, wherein the normal tissue reference profile is an average expression profile of said at least one nucleic acid in a plurality of reference biological samples of cancer-free subjects and wherein said expression profiles are determined using RT-PCR or nucleic acid arrays.

Additionally, Afar et al teach said expression profiles being determined using RT-PCR or nucleic acid arrays (e.g., page 53, line 6-13).

With regard to claims 5 and 6, it is noted that Afar et al do not expressly teach that the normal tissue reference profile is an "average" expression profile of said nucleic acid from cancer-free subjects. Nevertheless, it would have been *prima facie* obvious to one ordinarily skilled in the art at the time the invention was made to measure the

expression profile of said at least one nucleic acid in more than one reference biological sample, and then determine the average value of the expression profiles of that nucleic acid in the samples, so as to compare the expression profile of the nucleic acid in the colon cancer tissue and the average value in cancer-free colon tissue or to compare the expression profile of the nucleic acid in the lung cancer tissue and the average value in cancer-free lung tissue, because it would be recognized that the average value better reflects the standard level of expression in normal, non-cancerous colon or lung tissues. This is because it would be expected that the normal level of expression of any nucleic acid will vary in normal subjects, at least to some extent, such that the difference in the levels of expression in the colon or lung cancer tissue and any one specimen of the corresponding normal tissue might be more or less significant, which could lead the practitioner of the process to falsely conclude that the nucleic acid is or is not overexpressed in the cancerous tissue. Therefore, one ordinarily skilled in the art at the time the invention was made to would have been motivated to do so in order to more accurately determine whether or not the nucleic acid is overexpressed in the colon or lung cancer tissue, relative to the standard level of expression that occurs in the corresponding normal tissues.

Because Afar et al. teaches the expression profiles are determined using RT-PCR or nucleic acid array, it would have been *prima facie* obvious to determine the average value of the expression profiles of that nucleic acid in the samples using such methodology. One ordinarily skilled in the art would have been motivated to do so because such methodology was both routine and conventional at the time the invention was made, and was recognized to be very sensitive.

18. Claims 1, 5-7, 26 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 6,632,936 (Carr, published 2003), in view of US Patent 7,101,985 (Elledge et al, published 2006) and US Patent 6,709,832 (Von Knebel Doeberitz et al, published 2004).

The claims are herein drawn to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:1 in a colon cancer tissue from a human

subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:1 from normal colon tissue to determine whether said nucleic acid is overexpressed in the cancer tissue or to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:1 in a lung cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:1 from normal lung tissue to determine whether said nucleic acid is overexpressed in the cancer tissue. Claims 5 and 6 are further drawn to the method of claim 1, wherein the normal tissue reference profile is an average expression profile of said at least one nucleic acid in a plurality of reference biological samples of cancer-free subjects and wherein said expression profiles are determined using RT-PCR or nucleic acid arrays.

Carr teaches methods of detecting an expression profile of an mRNA that encodes a cell-cycle checkpoint polypeptide comprising SEQ ID NO:1 from lung cancer tissues that is 99.7% identical³ to the instantly claimed SEQ ID NO:1. Carr also teaches methods of detecting an expression profile of an mRNA that encodes a cell-cycle checkpoint polypeptide comprising SEQ ID NO:1 from colon cancer tissues that is 99.7% identical to the instantly claimed SEQ ID NO:1; see entire document (e.g., column 5, lines 11-33). Carr also teaches said expression profiles being determined using RT-PCR or nucleic acid arrays (e.g., column 5, lines 17-25).

Carr does not expressly teach an mRNA that is 100% identical to the instantly claimed nucleic acid comprising the sequence set forth as SEQ ID NO: 1, nor does Carr expressly teach comparing the expression profile of the mRNA from the colon or lung cancer tissue to the expression profile of the mRNA from corresponding normal colon or lung tissue, respectively, to determine whether said nucleic acid is overexpressed in the cancer tissue.

These deficiencies are made up for in the teachings of Elledge et al and Von Knebel Doeberitz et al.

Elledge et al teach an mRNA comprising a nucleotide sequence (i.e., SEQ ID

³ See the alignment of these sequences attached here as Exhibit B.

NO: 38), which encodes the **same** cell-cycle polypeptide as the polypeptide referred to by Carr, which is encoded by the disclosed nucleic acid molecule comprising SEQ ID NO: 1. Moreover, the nucleotide sequence of SEQ ID NO: 38, which is disclosed by Elledge et al., is 100% identical⁴ to SEQ ID NO: 1; see entire document (e.g., column 53, line 61 to column 54, line 16).

Von Knebel Doeberitz et al teach that it is an obvious thing to compare an mRNA expression profile from a cancerous body sample with a corresponding mRNA expression profile from a body sample which originates from a healthy person) (see entire document, e.g., column 2 lines 45-48 and 59-60).

Therefore, because it would be recognized that both the nucleic acid molecules disclosed by the prior art (i.e., the nucleic acid disclosed by Carr and the nucleic acid disclosed by Elledge et al.) encode the same protein, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to practice the process disclosed by Carr by detecting the expression profile of the nucleic acid disclosed by Elledge et al in both lung cancer tissue and colon cancer tissue. Furthermore, because Von Knebel Doeberitz et al teach that it is an obvious thing to compare an mRNA expression profile from a cancerous body sample with a corresponding mRNA expression profile from a body sample which originates from a healthy person, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to compare said colon cancer expression profile to the expression profile of the same nucleic acid in normal colon tissue or to compare said lung cancer expression profile to the expression profile of the same nucleic acid in normal lung tissue, to determine whether the nucleic acid encoding the protein is overexpressed in the cancer tissue.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to detect expression profiles of the mRNA comprising SEQ ID NO:38 of Elledge as it encodes the same cell-cycle checkpoint polypeptide of Carr. Notably, the polynucleotide sequence

⁴ See the alignment of these sequences attached here as Exhibit C.

of SEQ ID NO:38 of Elledge adds an additional 26 nucleotides to the 5' untranslated region of the mRNA taught by Carr and therefore, one of skill in the art would have been motivated to detect the mRNA of Elledge as one of ordinary skill in the art would have recognized it to be a more complete mRNA than the mRNA of Carr. Furthermore, one of ordinary skill in the art would have been motivated to compare the expression profile of the mRNA comprising SEQ ID NO:38 from the colon cancer tissue to its expression profile in corresponding normal colon tissue or to compare the expression profile of the mRNA comprising SEQ ID NO:38 from the lung cancer tissue to its expression profile in corresponding normal lung tissue as Von Knebel Doeberitz et al teach that it is obvious to compare a tissue suspected of being cancerous with a corresponding normal tissue, in order to detect cancer markers overexpressed in the cancerous tissue.

Additionally, as Elledge et al teach an mRNA with the same nucleotide sequence as the instantly claimed nucleic acid sequence there is a reasonable expectation of success in detecting and comparing expression profiles of said polynucleotide by the methods of Carr and Von Knebel Doeberitz.

With regard to claims 5 and 6, it is noted that Von Knebel Doeberitz et al do not expressly teach that the normal tissue expression profile is an "average" expression profile of said nucleic acid from cancer-free subjects. Nevertheless, it would have been *prima facie* obvious to one ordinarily skilled in the art at the time the invention was made to measure the expression profile of said at least one nucleic acid in more than one reference biological sample, and then determine the average value of the expression profiles of that nucleic acid in the samples, so as to compare the expression profile of the nucleic acid in the colon cancer tissue and the average value in cancer-free colon tissue or to compare the expression profile of the nucleic acid in the lung cancer tissue and the average value in cancer-free lung tissue, because it would be recognized that the average value better reflects the standard level of expression in normal, non-cancerous colon or lung tissues. This is because it would be expected that the normal level of expression of any nucleic acid will vary in normal subjects, at least to some extent, such that the difference in the levels of expression in the colon or lung cancer tissue and any one specimen of the corresponding normal tissue might be more or less

significant, which could lead the practitioner of the process to falsely conclude that the nucleic acid is or is not overexpressed in the cancerous tissue. Therefore, one ordinarily skilled in the art at the time the invention was made would have been motivated to do so in order to more accurately determine whether or not the nucleic acid is overexpressed in the colon or lung cancer tissue, relative to the standard level of expression that occurs in the corresponding normal tissues.

Because Carr teaches the expression profiles are determined using RT-PCR or nucleic acid array, it would have been *prima facie* obvious to determine the average value of the expression profiles of that nucleic acid in the samples using such methodology. One ordinarily skilled in the art would have been motivated to do so because such methodology was both routine and conventional at the time the invention was made, and was recognized to be very sensitive.

Thus, there would be an advantage and a reasonable expectation of success in detecting an expression profile of a nucleic acid comprising SEQ ID NO:1 in a colon cancer tissue from a human subject and comparing said expression profile to an average expression profile of a nucleic acid comprising SEQ ID NO:1 from colon tissue obtained from cancer-free subjects or in detecting an expression profile of a nucleic acid comprising SEQ ID NO:1 in a lung cancer tissue from a human subject and comparing said expression profile to an average expression profile of a nucleic acid comprising SEQ ID NO:1 from lung tissue obtained from cancer-free subjects using RT-PCR or nucleic acid array, to determine whether said nucleic acid is overexpressed in the cancer tissue, respectively, in view of US Patent and US Patent 6,632,936, US Patent 7,101,985 and US Patent 6,709,832.

19. Claims 1, 5-7, 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 7,081,340 (Baker et al, published 2006), in view of US Patent 6,709,832 (Von Knebel Doeberitz et al, published 2004).

The claims are herein drawn to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:12 in a colon cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:12 from normal colon tissue to determine whether said nucleic acid is overexpressed in the cancer tissue or to methods comprising detecting an expression profile of a nucleic acid comprising SEQ ID NO:12 in a lung cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:12 from normal lung tissue to determine whether said nucleic acid is overexpressed in the cancer tissue. Claims 5 and 6 are further drawn to the method of claim 1, wherein the normal tissue reference profile is an average expression profile of said at least one nucleic acid in a plurality of reference biological samples of cancer-free subjects and wherein said expression profiles are determined using RT-PCR or nucleic acid arrays.

Baker et al teach methods of detecting an expression profile of an mRNA comprising SEQ ID NO:295 in colon cancer tissue that is 100% identical⁵ to the instantly claimed SEQ ID NO:12 and comparing said expression profile to the expression profile of an mRNA comprising SEQ ID NO:295 from a cancer tissue reference expression profile set. Baker et al also teach methods of detecting an expression profile of an mRNA comprising SEQ ID NO:295 in lung cancer tissue that is 100% identical to the instantly claimed SEQ ID NO:12 and comparing said expression profile to the expression profile of an mRNA comprising SEQ ID NO:295 from a cancer tissue reference expression profile set; see entire document (e.g., column 2, lines 34-44, column 5, lines, 43-63) Baker et al also teach said expression profiles being determined using RT-PCR (see e.g., column 4, lines 43-60).

Baker et al do not expressly teach comparing the lung or colon cancer tissue expression profile to a corresponding normal tissue reference profile.

This deficiency is made up for in the teachings of Von Knebel Doeberitz et al.

Von Knebel Doeberitz et al teach that it is an obvious thing to compare an mRNA

⁵ See the alignment of these sequences attached here as Exhibit D.

expression profile from a cancerous body sample with a corresponding mRNA expression profile from a body sample which originates from a healthy person) (see entire document, e.g., column 2 lines 45-48 and 59-60).

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to compare the expression profile of an mRNA comprising SEQ ID NO:12 in lung cancer tissues to the expression profile of an mRNA comprising SEQ ID NO:12 in corresponding normal lung tissue from subjects without cancer or to compare the expression profile of an mRNA comprising SEQ ID NO:12 in colon cancer tissues to the expression profile of an mRNA comprising SEQ ID NO:12 in corresponding normal colon tissue from subjects without cancer, in order to compare the expression profiles to determine whether said mRNA is overexpressed in the cancer tissue.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to detect an expression profile of a nucleic acid comprising SEQ ID NO:12 in a colon or lung cancer tissue from a human subject and comparing said expression profile to the expression profile of a nucleic acid comprising SEQ ID NO:12 from normal colon or lung tissue, respectively to determine whether said nucleic acid is overexpressed in the cancer tissue because Baker et al teach methods of detecting an mRNA that is 100% identical to SEQ ID NO:12 in colon and lung cancer tissue and Von Knebel Doeberitz et al teach that it is obvious to compare a tissue suspected of being cancerous with a corresponding normal tissue, in order to detect cancer markers overexpressed in the cancerous tissue.

With regard to claims 5 and 6, it is noted that Von Knebel Doeberitz et al do not expressly teach that the normal tissue expression profile is an "average" expression profile of said nucleic acid from cancer-free subjects. Nevertheless, it would have been *prima facie* obvious to one ordinarily skilled in the art at the time the invention was made to measure the expression profile of said at least one nucleic acid in more than one reference biological sample, and then determine the average value of the expression profiles of that nucleic acid in the samples, so as to compare the expression profile of

the nucleic acid in the colon cancer tissue and the average value in cancer-free colon tissue or to compare the expression profile of the nucleic acid in the lung cancer tissue and the average value in cancer-free lung tissue, because it would be recognized that the average value better reflects the standard level of expression in normal, non-cancerous colon or lung tissues. This is because it would be expected that the normal level of expression of any nucleic acid will vary in normal subjects, at least to some extent, such that the difference in the levels of expression in the colon or lung cancer tissue and any one specimen of the corresponding normal tissue might be more or less significant, which could lead the practitioner of the process to falsely conclude that the nucleic acid is or is not overexpressed in the cancerous tissue. Therefore, one ordinarily skilled in the art at the time the invention was made to would have been motivated to do so in order to more accurately determine whether or not the nucleic acid is overexpressed in the colon or lung cancer tissue, relative to the standard level of expression that occurs in the corresponding normal tissues.

Because Baker et al teach the expression profiles are determined using RT-PCR, it would have been *prima facie* obvious to determine the average value of the expression profiles of that nucleic acid in the samples using such methodology. One ordinarily skilled in the art would have been motivated to do so because such methodology was both routine and conventional at the time the invention was made, and was recognized to be very sensitive. Additionally, it is noted that Baker et al do not expressly teach using nucleic acid arrays to determine said expression profiles. Nevertheless, it would have been *prima facie* obvious to one ordinarily skilled in the art at the time the invention was made to measure the expression profiles by nucleic acid array or by RT-PCR as both technologies were recognized to be used in methods to provide mRNA expression profiles. One ordinarily skilled in the art would have been motivated to do so because both methodologies were routine and conventional at the time the invention was made, and were recognized to be used in methods to determine mRNA expression profiles.

Thus, there would be an advantage and a reasonable expectation of success in detecting an expression profile of a nucleic acid comprising SEQ ID NO:12 in a colon

cancer tissue from a human subject and comparing said expression profile to an average expression profile of a nucleic acid comprising SEQ ID NO:12 from colon tissue obtained from cancer-free subjects or in detecting an expression profile of a nucleic acid comprising SEQ ID NO:12 in a lung cancer tissue from a human subject and comparing said expression profile to an average expression profile of a nucleic acid comprising SEQ ID NO:12 from lung tissue obtained from cancer-free subjects using RT-PCR or nucleic acid array, to determine whether said nucleic acid is overexpressed in the cancer tissue, respectively, in view of US Patent 7,081,340 and US Patent 6,709,832.

Conclusion

20. No claim is allowed.

21. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brad Duffy whose telephone number is (571) 272-9935. The examiner can normally be reached on Monday through Friday 7:00 AM to 4:30 PM

with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Respectfully,
Brad Duffy
571-272-9935

/Stephen L. Rawlings/
Stephen L. Rawlings, Ph.D.
Primary Examiner, Art Unit 1643

bd
August 17, 2007

Exhibit A

```

<!--StartFragment-->RESULT 8
ACC72688
ID ACC72688 standard; cDNA; 2119 BP.
XX
AC ACC72688;
XX
DT 09-JUL-2003 (first entry)
XX
DE Human cancer related protein encoding cDNA SEQ ID NO:27.
XX
KW Human; cancer; diagnosis; screening; modulator; leukaemia; ischaemia;
KW heart disease; atherosclerosis; endometriosis; gene; ss.
XX
OS Homo sapiens.
XX
PN WO2003025138-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-US029560.
XX
PR 17-SEP-2001; 2001US-0323469P.
PR 20-SEP-2001; 2001US-0323887P.
PR 13-NOV-2001; 2001US-0350666P.
PR 08-FEB-2002; 2002US-0355145P.
PR 08-FEB-2002; 2002US-0355257P.
PR 12-APR-2002; 2002US-0372246P.
XX
PA (EOSB-) EOS BIOTECHNOLOGY INC.
XX
PI Afar D, Aziz N, Gish KC, Hevezi PA, Mack DH, Wilson KE;
PI Zlotnik A;
XX
DR WPI; 2003-354600/33.
DR P-PSDB; ABR58565.
XX
PT New genes that are up-regulated or down-regulated in cancers, useful as
PT markers for diagnosing e.g. cancer, ischemia or heart diseases, or as
PT therapeutic targets for screening drugs for treating these diseases.
XX
PS Claim 8; Page 641; 767pp; English.
XX
CC The present invention describes an isolated nucleic acid molecule, which
CC comprises the sequence of any of the genes that are up-regulated or down-
CC regulated in specific cancers (e.g. about 1031 genes up-regulated in
CC acute lymphocytic leukemia). ACC72641 to ACC72860 represent cancer
CC related gene nucleotide sequences which encode the proteins given in
CC ABR58521 to ABR58709. Also described: (1) determining the presence or
CC absence of a pathological cell in a patient; (2) an expression vector
CC comprising a nucleic acid molecule described above; (3) a host cell
CC comprising the vector; (4) an isolated polypeptide, which is encoded by
CC the nucleic acid; (5) an antibody that specifically binds the polypeptide
CC of (4); (6) specifically targeting a compound to a pathological cell in a
CC patient by administering to the patient the antibody above; and (7) a
CC drug screening assay. The nucleic acid is useful as diagnostic markers or
CC therapeutic targets. In particular, the nucleic acid is useful for
CC diagnosing a pathology, e.g. cancer (e.g. cancer of the bone marrow,
CC bladder, brain, breast, cervix, colon/rectum, kidney, lung, ovary,
CC pancreas, prostate, skin and uterus), wounds, ischaemia, heart diseases,
CC atherosclerosis and endometriosis. The nucleic acid is also useful in
CC drug screening, particularly for identifying agents for treating these
CC pathologies
XX
SQ Sequence 2119 BP; 646 A; 389 C; 492 G; 592 T; 0 U; 0 Other;

Query Match 100.0%; Score 2119; DB 10; Length 2119;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCACGAGTAGGGGTGGCGGGTCAGTGCTGCTCGGGGGCTTCTCCATCCAGGTCCTGGA 60
Db 1 GGCACGAGTAGGGGTGGCGGGTCAGTGCTGCTCGGGGGCTTCTCCATCCAGGTCCTGGA 60

Qy 61 GTTCCTGGTCCCTGGAGCTCCGCACTTGGCGGCAACCTGCGTGAGGCAGCGGACTCTG 120
Db 61 GTTCCTGGTCCCTGGAGCTCCGCACTTGGCGGCAACCTGCGTGAGGCAGCGGACTCTG 120

```

Qy 121 GCGACTGGCCGGCCATGCCTTCCCGGGCTGAGGACTATGAAGTGTGTACACCATTGGCA 180
|||||
Db 121 GCGACTGGCCGGCCATGCCTTCCCGGGCTGAGGACTATGAAGTGTGTACACCATTGGCA 180

Qy 181 CAGGCTCCTACGGCCGCTGCCAGAAGATCCGGAGGAAGAGTGATGGCAAGATATTAGTTT 240
|||||
Db 181 CAGGCTCCTACGGCCGCTGCCAGAAGATCCGGAGGAAGAGTGATGGCAAGATATTAGTTT 240

Qy 241 GGAAAGAACTTGACTATGGCTCCATGACAGAAGCTGAGAAACAGATGCTTGTCTGAAG 300
|||||
Db 241 GGAAAGAACTTGACTATGGCTCCATGACAGAAGCTGAGAAACAGATGCTTGTCTGAAG 300

Qy 301 TGAATTTGCTTCGTGAAGTGAACATCCAAACATCGTTCGTTACTATGATCGGATTATTG 360
|||||
Db 301 TGAATTTGCTTCGTGAAGTGAACATCCAAACATCGTTCGTTACTATGATCGGATTATTG 360

Qy 361 ACCGGACCAATACAACACTGTACATTGTAATGGAATATTGTGAAGGAGGGGATCTGGCTA 420
|||||
Db 361 ACCGGACCAATACAACACTGTACATTGTAATGGAATATTGTGAAGGAGGGGATCTGGCTA 420

Qy 421 GTGTAATTACAAAGGGAACCAAGGAAAGGCAATACTTAGATGAAGAGTTTGTCTTCGAG 480
|||||
Db 421 GTGTAATTACAAAGGGAACCAAGGAAAGGCAATACTTAGATGAAGAGTTTGTCTTCGAG 480

Qy 481 TGATGACTCAGTTGACTCTGGCCCTGAAGGAATGCCACAGACGAAGTGATGGTGGTCATA 540
|||||
Db 481 TGATGACTCAGTTGACTCTGGCCCTGAAGGAATGCCACAGACGAAGTGATGGTGGTCATA 540

Qy 541 CCGTATTGCATCGGGATCTTAAACCAGCCAATGTTTTCCTGGATGGCAAGCAAAACGTCA 600
|||||
Db 541 CCGTATTGCATCGGGATCTTAAACCAGCCAATGTTTTCCTGGATGGCAAGCAAAACGTCA 600

Qy 601 AGCTTGGAGACTTTGGGCTAGCTAGAATATTAAACCATGACACGAGTTTGC AAAACAT 660
|||||
Db 601 AGCTTGGAGACTTTGGGCTAGCTAGAATATTAAACCATGACACGAGTTTGC AAAACAT 660

Qy 661 TTGTTGGCACACCTTATTACATGTCTCCTGAACAAATGAATCGCATGTCTACAATGAGA 720
|||||
Db 661 TTGTTGGCACACCTTATTACATGTCTCCTGAACAAATGAATCGCATGTCTACAATGAGA 720

Qy 721 AATCAGATATCTGGTCATTGGGCTGCTTGTGTATGAGTTATGTGCATTAAATGCCTCCAT 780
|||||
Db 721 AATCAGATATCTGGTCATTGGGCTGCTTGTGTATGAGTTATGTGCATTAAATGCCTCCAT 780

Qy 781 TTACAGCTTTTAGCCAGAAAGAACTCGCTGGGAAATCAGAGAAGGCAAATTCAGGCGAA 840
|||||
Db 781 TTACAGCTTTTAGCCAGAAAGAACTCGCTGGGAAATCAGAGAAGGCAAATTCAGGCGAA 840

Qy 841 TTCCATACCGTTACTCTGATGAATTGAATGAAATTATTACGAGGATGTTAACTTAAAGG 900
|||||
Db 841 TTCCATACCGTTACTCTGATGAATTGAATGAAATTATTACGAGGATGTTAACTTAAAGG 900

Qy 901 ATTACCATCGACCTTCTGTTGAAGAAATCTTGAGAACCCTTTAATAGCAGATTGGTTG 960
|||||
Db 901 ATTACCATCGACCTTCTGTTGAAGAAATCTTGAGAACCCTTTAATAGCAGATTGGTTG 960

Qy 961 CAGACGAGCAAAGAAGAAATCTTGAGAGAAGAGGGCGACAATTAGGAGAGCCAGAAAAAT 1020
|||||
Db 961 CAGACGAGCAAAGAAGAAATCTTGAGAGAAGAGGGCGACAATTAGGAGAGCCAGAAAAAT 1020

Qy 1021 CGCAGGATTCCAGCCCTGTATTGAGTGAGCTGAAACTGAAGGAAATTCAGTTACAGGAGC 1080
|||||
Db 1021 CGCAGGATTCCAGCCCTGTATTGAGTGAGCTGAAACTGAAGGAAATTCAGTTACAGGAGC 1080

Qy 1081 GAGAGCGAGCTCTCAAAGCAAGAGAAGAAAGATTGGAGCAGAAAGAACAGGAGCTTTGTG 1140
|||||
Db 1081 GAGAGCGAGCTCTCAAAGCAAGAGAAGAAAGATTGGAGCAGAAAGAACAGGAGCTTTGTG 1140

Qy 1141 TTCGTGAGAGACTAGCAGAGGACAACTGGCTAGAGCAGAAATCTGTTGAAGAACTACA 1200
|||||
Db 1141 TTCGTGAGAGACTAGCAGAGGACAACTGGCTAGAGCAGAAATCTGTTGAAGAACTACA 1200

Qy 1201 GCTTGCTAAAGGAACGGAAGTTCCTGTCTCTGGCAAGTAATCCAGAACTTCTTAATCTTC 1260
|||||
Db 1201 GCTTGCTAAAGGAACGGAAGTTCCTGTCTCTGGCAAGTAATCCAGAACTTCTTAATCTTC 1260

QY 1261 CATCCTCAGTAATTAAGAAGAAAGTTTCATTTTCAGTGGGAAAGTAAAGAGAACATCATGA 1320
|||||
Db 1261 CATCCTCAGTAATTAAGAAGAAAGTTTCATTTTCAGTGGGAAAGTAAAGAGAACATCATGA 1320

QY 1321 GGAGTGAGAATTCTGAGAGTCAGCTCACATCTAAGTCCAAGTGCAAGGACCTGAAGAAAA 1380
|||||
Db 1321 GGAGTGAGAATTCTGAGAGTCAGCTCACATCTAAGTCCAAGTGCAAGGACCTGAAGAAAA 1380

QY 1381 GGCTTCACGCTGCCAGCTGCGGGCTCAAGCCCTGTGAGATATTGAGAAAAATTACCAAC 1440
|||||
Db 1381 GGCTTCACGCTGCCAGCTGCGGGCTCAAGCCCTGTGAGATATTGAGAAAAATTACCAAC 1440

QY 1441 TGAAGAAGCAGACAGATCCTGGGCATGCGCTAGCCAGGTAGAGAGACACAGAGCTGTGTAC 1500
|||||
Db 1441 TGAAGAAGCAGACAGATCCTGGGCATGCGCTAGCCAGGTAGAGAGACACAGAGCTGTGTAC 1500

QY 1501 AGGATGTAATATTACCAACCTTTAAAGACTGATATTCAAATGCTGTAGTTGAATACTT 1560
|||||
Db 1501 AGGATGTAATATTACCAACCTTTAAAGACTGATATTCAAATGCTGTAGTTGAATACTT 1560

QY 1561 GGCCCCATGAGCCATGCCTTTCTGTATAGTACACATGATATTCGGAATTGGTTTTACTG 1620
|||||
Db 1561 GGCCCCATGAGCCATGCCTTTCTGTATAGTACACATGATATTCGGAATTGGTTTTACTG 1620

QY 1621 TTCTTCAGCAACTATTGTACAAAATGTTACATTTAATTTTCTTCTTTTAAAGAAC 1680
|||||
Db 1621 TTCTTCAGCAACTATTGTACAAAATGTTACATTTAATTTTCTTCTTTTAAAGAAC 1680

QY 1681 ATATTATAAAGAATACTTTCTTGGTTGGGCTTTAATCCTGTGTGTGATTACTAGTAG 1740
|||||
Db 1681 ATATTATAAAGAATACTTTCTTGGTTGGGCTTTAATCCTGTGTGTGATTACTAGTAG 1740

QY 1741 GAACATGAGATGTGACATTCTAAATCTTGGGAGAAAAAATAATATTAGGAAAAAATATT 1800
|||||
Db 1741 GAACATGAGATGTGACATTCTAAATCTTGGGAGAAAAAATAATATTAGGAAAAAATATT 1800

QY 1801 TATGCAGGAAGAGTAGCACTCACTGAATAGTTTAAATGACTGAGTGGTATGCTTACAAT 1860
|||||
Db 1801 TATGCAGGAAGAGTAGCACTCACTGAATAGTTTAAATGACTGAGTGGTATGCTTACAAT 1860

QY 1861 TGTCATGTCTAGATTTAAATTTAAGTCTGAGATTTAAATGTTTTGAGCTTAGAAAAC 1920
|||||
Db 1861 TGTCATGTCTAGATTTAAATTTAAGTCTGAGATTTAAATGTTTTGAGCTTAGAAAAC 1920

QY 1921 CCAGTTAGATGCAATTTGGTCATTAATACCATGACATCTTGCTTATAAATATTCCATTGC 1980
|||||
Db 1921 CCAGTTAGATGCAATTTGGTCATTAATACCATGACATCTTGCTTATAAATATTCCATTGC 1980

QY 1981 TCTGTAGTTCAAATCTGTTAGCTTTGTGAAAATTCATCACTGTGATGTTTGTATTCTTTT 2040
|||||
Db 1981 TCTGTAGTTCAAATCTGTTAGCTTTGTGAAAATTCATCACTGTGATGTTTGTATTCTTTT 2040

QY 2041 TTTTTTCTGTTTAAACAGAATATGAGCTGTCTGTCATTTACCTACTTCTTTCCCACTAAA 2100
|||||
Db 2041 TTTTTTCTGTTTAAACAGAATATGAGCTGTCTGTCATTTACCTACTTCTTTCCCACTAAA 2100

QY 2101 TAAAAGAATTCTTCAGTTA 2119
|||||
Db 2101 TAAAAGAATTCTTCAGTTA 2119

<!--EndFragment-->

Exhibit B

<!--StartFragment-->RESULT 3

US-09-029-047C-1

; Sequence 1, Application US/09029047C

; Patent No. 6632936

; GENERAL INFORMATION:

; APPLICANT: Carr, Antony M.

; TITLE OF INVENTION: Cell-Cycle Checkpoint Genes

; FILE REFERENCE: 27866/34132

; CURRENT APPLICATION NUMBER: US/09/029,047C

; CURRENT FILING DATE: 1999-05-11

; PRIOR APPLICATION NUMBER: PCT/GB96/02197

; PRIOR FILING DATE: 1996-09-06

; PRIOR APPLICATION NUMBER: GB 9518220.0

; PRIOR FILING DATE: 1995-09-06

; NUMBER OF SEQ ID NOS: 14

; SOFTWARE: PatentIn Ver. 3.1

; SEQ ID NO 1

; LENGTH: 8239

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (80)..(8011)

US-09-029-047C-1

Query Match 99.7%; Score 8237.4; DB 3; Length 8239;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 8238; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy      27 GCGCTCTTCCGGCAGCGGTACGTTTGGAGACGCCGGGAACCCGCGTTGGCGTGGTTGACT 86
      |||
Db      1 GCGCTCTTCCGGCAGCGGTACGTTTGGAGACGCCGGGAACCCGCGTTGGCGTGGTTGACT 60

Qy      87 AGTGCCTCGCAGCCTCAGCATGGGGGAACATGGCCTGGAGCTGGCTTCCATGATCCCCGC 146
      . |||
Db      61 AGTGCCTCGCAGCCTCAGCATGGGGGAACATGGCCTGGAGCTGGCTTCCATGATCCCCGC 120

Qy     147 CCTGCGGGAGCTGGGCAGTGCCACACCAGAGGAATATAATACAGTTGTACAGAAGCCAAG 206
      |||
Db     121 CCTGCGGGAGCTGGGCAGTGCCACACCAGAGGAATATAATACAGTTGTACAGAAGCCAAG 180

Qy     207 ACAAAATTCTGTGTCAATTATTGACCGGATACTTACAGATGTAATGTTGTTGCTGTAGA 266
      |||
Db     181 ACAAAATTCTGTGTCAATTATTGACCGGATACTTACAGATGTAATGTTGTTGCTGTAGA 240

Qy     267 ACTTGTAAGAAAACCTGACTCTCAGCCAACCTCCGTGATGTTGCTTGATTTTATCCAGCA 326
      |||
Db     241 ACTTGTAAGAAAACCTGACTCTCAGCCAACCTCCGTGATGTTGCTTGATTTTATCCAGCA 300

Qy     327 TATCATGAAATCCTCCCCACTTATGTTTGTAAATGTGAGTGAAGCCATGAGCGCAAAGG 386
      |||
Db     301 TATCATGAAATCCTCCCCACTTATGTTTGTAAATGTGAGTGAAGCCATGAGCGCAAAGG 360

Qy     387 CAGTTGTATTGAATTCAAGTAATTGGATCATAACGAGACTTCTGCGGATTGCAGCAACTCC 446
      |||
Db     361 CAGTTGTATTGAATTCAAGTAATTGGATCATAACGAGACTTCTGCGGATTGCAGCAACTCC 420

Qy     447 CTCCTGTCAATTTGTTACACAAGAAAATCTGTGAAGTCATCTGTTTATTATTCTTTT 506
      |||
Db     421 CTCCTGTCAATTTGTTACACAAGAAAATCTGTGAAGTCATCTGTTTATTATTCTTTT 480

Qy     507 TAAAAGCAAGAGTCCTGCTATTTTGGGGTACTCACAAAAGAATTATTACAACCTTTTGA 566
      |||
Db     481 TAAAAGCAAGAGTCCTGCTATTTTGGGGTACTCACAAAAGAATTATTACAACCTTTTGA 540

Qy     567 AGACTTGGTTTACCTCCATAGAAGAAATGTGATGGGTCATGCTGTGGAATGGCCAGTGGT 626
      |||
Db     541 AGACTTGGTTTACCTCCATAGAAGAAATGTGATGGGTCATGCTGTGGAATGGCCAGTGGT 600

Qy     627 CATGAGCCGATTTTAAAGTCAATTAGATGAACACATGGGATATTTACAATCAGCTCCTTT 686
      |||
Db     601 CATGAGCCGATTTTAAAGTCAATTAGATGAACACATGGGATATTTACAATCAGCTCCTTT 660

Qy     687 GCAGTTGATGAGTATGCAAATTTAGAATTTATTGAAGTCACTTTATTAATGGTTCTTAC 746
      |||
Db     661 GCAGTTGATGAGTATGCAAATTTAGAATTTATTGAAGTCACTTTATTAATGGTTCTTAC 720

```

Qy	747	TCGTATTATTGCAATTGTGTTTTTAGAAGGCAAGAACTCTTACTTTGGCAGATAGGTTG	806
Db	721	TCGTATTATTGCAATTGTGTTTTTAGAAGGCAAGAACTCTTACTTTGGCAGATAGGTTG	780
Qy	807	TGTTCTGCTAGAGTATGGTAGTCCAAAAATTAAATCCCTAGCAATTAGCTTTTAAACAGA	866
Db	781	TGTTCTGCTAGAGTATGGTAGTCCAAAAATTAAATCCCTAGCAATTAGCTTTTAAACAGA	840
Qy	867	ACTTTTTTCAGCTTGGAGGACTACCAGCACAAACCAGCTAGCACTTTTTTCAGCTCATTTTT	926
Db	841	ACTTTTTTCAGCTTGGAGGACTACCAGCACAAACCAGCTAGCACTTTTTTCAGCTCATTTTT	900
Qy	927	GGAATTATTAAAACACCTTGTAGAAATGGATACTGACCAATTGAAACTCTATGAAGAGCC	986
Db	901	GGAATTATTAAAACACCTTGTAGAAATGGATACTGACCAATTGAAACTCTATGAAGAGCC	960
Qy	987	ATTATCAAAGCTGATAAAGACACTATTTCCCTTTGAAGCAGAAGCTTATAGAAATATTGA	1046
Db	961	ATTATCAAAGCTGATAAAGACACTATTTCCCTTTGAAGCAGAAGCTTATAGAAATATTGA	1020
Qy	1047	ACCTGCTCTATTTAAATATGCTGCTGGAAAACTCTGTGTCATGTTGAAGACGGTGTGCT	1106
Db	1021	ACCTGCTCTATTTAAATATGCTGCTGGAAAACTCTGTGTCATGTTGAAGACGGTGTGCT	1080
Qy	1107	CATGGGGCTTAAGTCTGATTTGCTAAAAGCAGCTTTGTGCCATTTACTGCAGTATTTCT	1166
Db	1081	CATGGGGCTTAAGTCTGATTTGCTAAAAGCAGCTTTGTGCCATTTACTGCAGTATTTCT	1140
Qy	1167	TAAATTTGTGCCAGCTGGGTATGAATCTGCTTTACAAGTCAGGAAGGTCTATGTGAGAAA	1226
Db	1141	TAAATTTGTGCCAGCTGGGTATGAATCTGCTTTACAAGTCAGGAAGGTCTATGTGAGAAA	1200
Qy	1227	TATTTGTAAAGCTCTTTTGGATGTGCTTGAATTGAGGTAGATGCAGAGTACTTGTGGG	1286
Db	1201	TATTTGTAAAGCTCTTTTGGATGTGCTTGAATTGAGGTAGATGCAGAGTACTTGTGGG	1260
Qy	1287	CCCACTTTATGCAGCTTTGAAAATGGAAAGTATGGAATCATTGAGGAGATTCAATGCCA	1346
Db	1261	CCCACTTTATGCAGCTTTGAAAATGGAAAGTATGGAATCATTGAGGAGATTCAATGCCA	1320
Qy	1347	AACTCAACAGGAAAACCTCAGCAGTAATAGTGATGGAATATCACCCAAAAGGCGTCGTCT	1406
Db	1321	AACTCAACAGGAAAACCTCAGCAGTAATAGTGATGGAATATCACCCAAAAGGCGTCGTCT	1380
Qy	1407	CAGCTCGTCTCTAAACCCTTCTAAAAGAGCACCAAAACAGACTGAGGAAATTAAACATGT	1466
Db	1381	CAGCTCGTCTCTAAACCCTTCTAAAAGAGCACCAAAACAGACTGAGGAAATTAAACATGT	1440
Qy	1467	GGACATGAACCAAAAGAGCATATTATGGAGTGCACTGAAACAGAAAGCTGAATCCCTTCA	1526
Db	1441	GGACATGAACCAAAAGAGCATATTATGGAGTGCACTGAAACAGAAAGCTGAATCCCTTCA	1500
Qy	1527	GATTTCCCTTGAATACAGTGGCCTAAAGAATCCTGTTATTGAGATGTTAGAAGGAATTGC	1586
Db	1501	GATTTCCCTTGAATACAGTGGCCTAAAGAATCCTGTTATTGAGATGTTAGAAGGAATTGC	1560
Qy	1587	TGTTGTCTTACAACCTGACTGCTCTGTGTACTGTTCACTGTTCTCATCAAAACATGAACTG	1646
Db	1561	TGTTGTCTTACAACCTGACTGCTCTGTGTACTGTTCACTGTTCTCATCAAAACATGAACTG	1620
Qy	1647	CCGTACTTTCAAGGACTGTCAACATAAATCCAAGAAGAAACCTTCTGTAGTGATAACTTG	1706
Db	1621	CCGTACTTTCAAGGACTGTCAACATAAATCCAAGAAGAAACCTTCTGTAGTGATAACTTG	1680
Qy	1707	GATGTCATTGGATTTTTACACAAAAGTGCTTAAGAGCTGTAGAAGTTTGTAGAATCTGT	1766
Db	1681	GATGTCATTGGATTTTTACACAAAAGTGCTTAAGAGCTGTAGAAGTTTGTAGAATCTGT	1740
Qy	1767	TCAGAAACTGGACCTGGAGGCAACCATTGATAAGGTGGTAAAATTTATGATGCTTTGAT	1826
Db	1741	TCAGAAACTGGACCTGGAGGCAACCATTGATAAGGTGGTAAAATTTATGATGCTTTGAT	1800
Qy	1827	TTATATGCAAGTAAACAGTTCATTTGAAGATCATATCCTGGAAGATTTATGTGGTATGCT	1886
Db	1801	TTATATGCAAGTAAACAGTTCATTTGAAGATCATATCCTGGAAGATTTATGTGGTATGCT	1860

Qy	1887	CTCACTTCCATGGATTATTCCCATTCTGATGATGGCTGTTTAAAGTTGACCACATTTGC	1946
Db	1861	CTCACTTCCATGGATTATTCCCATTCTGATGATGGCTGTTTAAAGTTGACCACATTTGC	1920
Qy	1947	CGCTAATCTTCTAACATTAAGCTGTAGGATTTAGATAGCTATTACCACAGGCACAATC	2006
Db	1921	CGCTAATCTTCTAACATTAAGCTGTAGGATTTAGATAGCTATTACCACAGGCACAATC	1980
Qy	2007	ACGATGTGTGTTTCTTCTGACTCTGTTTCCAAGAAGAATATTCCTTGAGTGGAGAACAGC	2066
Db	1981	ACGATGTGTGTTTCTTCTGACTCTGTTTCCAAGAAGAATATTCCTTGAGTGGAGAACAGC	2040
Qy	2067	AGTTTACAACCTGGGCCCTGCAGAGCTCCCATGAAGTAATCCGGGCTAGTTGTGTTAGTGG	2126
Db	2041	AGTTTACAACCTGGGCCCTGCAGAGCTCCCATGAAGTAATCCGGGCTAGTTGTGTTAGTGG	2100
Qy	2127	ATTTTTTATCTTATTGCAGCAGCAGAATCTTGTAAACAGAGTTCCCAAGATTCTTATAGA	2186
Db	2101	ATTTTTTATCTTATTGCAGCAGCAGAATCTTGTAAACAGAGTTCCCAAGATTCTTATAGA	2160
Qy	2187	TAAAGTCAAAGATGATTCTGACATTGTCAAGAAAGAATTTGCTTCTATACTTGGTCAACT	2246
Db	2161	TAAAGTCAAAGATGATTCTGACATTGTCAAGAAAGAATTTGCTTCTATACTTGGTCAACT	2220
Qy	2247	TGTCTGTACTCTTCACGGCATGTTTTATCTGACAAGTTCTTTAACAGAACCTTTCTCTGA	2306
Db	2221	TGTCTGTACTCTTCACGGCATGTTTTATCTGACAAGTTCTTTAACAGAACCTTTCTCTGA	2280
Qy	2307	ACACGGACATGTGGACCTCTTCTGTAGGAACTGAAAGCCACTTCTCAACATGAATGTTT	2366
Db	2281	ACACGGACATGTGGACCTCTTCTGTAGGAACTGAAAGCCACTTCTCAACATGAATGTTT	2340
Qy	2367	ATCTTCTCAACTAAAAGCTTCTGTCTGCAAGCCATTCTTTTCTACTGAAAAAAAAAAT	2426
Db	2341	ATCTTCTCAACTAAAAGCTTCTGTCTGCAAGCCATTCTTTTCTACTGAAAAAAAAAAT	2400
Qy	2427	ACCTAGTCCAGTAAAAGCTTCTGTCTCATAGATAATCTACATCATCTTTGTAAGCATCTTGA	2486
Db	2401	ACCTAGTCCAGTAAAAGCTTCTGTCTCATAGATAATCTACATCATCTTTGTAAGCATCTTGA	2460
Qy	2487	TTTTAGAGAAGATGAAACAGATGTAAGAGCAGTTCTTGGAACTTTATTAAATTTAATGGA	2546
Db	2461	TTTTAGAGAAGATGAAACAGATGTAAGAGCAGTTCTTGGAACTTTATTAAATTTAATGGA	2520
Qy	2547	AGATCCAGACAAAGATGTTAGAGTGGCTTTTAGTGGAAATATCAAGCACATATTGGAATC	2606
Db	2521	AGATCCAGACAAAGATGTTAGAGTGGCTTTTAGTGGAAATATCAAGCACATATTGGAATC	2580
Qy	2607	CTTGGACTCTGAAGATGGATTTATAAGGAGCTTTTGTCTTAAGAATGAAGGAAGCATA	2666
Db	2581	CTTGGACTCTGAAGATGGATTTATAAGGAGCTTTTGTCTTAAGAATGAAGGAAGCATA	2640
Qy	2667	TACACATGCCCAATATCAAGAAATAATGAGCTGAAGGATACCTTGATTCTTACAACAGG	2726
Db	2641	TACACATGCCCAATATCAAGAAATAATGAGCTGAAGGATACCTTGATTCTTACAACAGG	2700
Qy	2727	GGATATTGGAAGGGCCGCAAAAGGAGATTTGGTACCATTGCACTCTTACACTTATTGCA	2786
Db	2701	GGATATTGGAAGGGCCGCAAAAGGAGATTTGGTACCATTGCACTCTTACACTTATTGCA	2760
Qy	2787	TTGTTTGTATCCAAGTCAGCATCTGTCTCTGGAGCAGCATACACAGAAATTAGAGCTCT	2846
Db	2761	TTGTTTGTATCCAAGTCAGCATCTGTCTCTGGAGCAGCATACACAGAAATTAGAGCTCT	2820
Qy	2847	GGTTGCAGCTAAAAGTGTTAAAGTCAAAGTTTTTTCAGCCAGTATAAGAAACCCATCTG	2906
Db	2821	GGTTGCAGCTAAAAGTGTTAAAGTCAAAGTTTTTTCAGCCAGTATAAGAAACCCATCTG	2880
Qy	2907	TCAGTTTTTGGTAGAATCCCTTCACTCTAGTCAGATGACAGCACTCCGAATACTCCATG	2966
Db	2881	TCAGTTTTTGGTAGAATCCCTTCACTCTAGTCAGATGACAGCACTCCGAATACTCCATG	2940
Qy	2967	CCAGAATGCTGACGTGCGAAAACAAGATGTGGCTCACCAGAGAGAAATGGCTTTAAATAC	3026
Db	2941	CCAGAATGCTGACGTGCGAAAACAAGATGTGGCTCACCAGAGAGAAATGGCTTTAAATAC	3000

Qy	3027	GTTGTCTGAAATTGCCAACGTTTTCGACTTTCCTGATCTTAATCGTTTTCTTACTAGGAC	3086
Db	3001	GTTGTCTGAAATTGCCAACGTTTTCGACTTTCCTGATCTTAATCGTTTTCTTACTAGGAC	3060
Qy	3087	ATTACAAGTTCTACTACCTGATCTTGCTGCCAAAGCAAGCCCTGCAGCTTCTGCTCTCAT	3146
Db	3061	ATTACAAGTTCTACTACCTGATCTTGCTGCCAAAGCAAGCCCTGCAGCTTCTGCTCTCAT	3120
Qy	3147	TCGAACCTTTAGGAAAACAATTAAATGTCAATCGTAGAGAGATTTTAATAAACAACTTCAA	3206
Db	3121	TCGAACCTTTAGGAAAACAATTAAATGTCAATCGTAGAGAGATTTTAATAAACAACTTCAA	3180
Qy	3207	ATATATTTTTTCTCATTTGGTCTGTTCTTGTTCCAAAGATGAATTAGAACGTGCCCTTCA	3266
Db	3181	ATATATTTTTTCTCATTTGGTCTGTTCTTGTTCCAAAGATGAATTAGAACGTGCCCTTCA	3240
Qy	3267	TTATCTGAAGAATGAAACAGAAATTGAACTGGGGAGCCTGTTGAGACAAGATTTCCAAGG	3326
Db	3241	TTATCTGAAGAATGAAACAGAAATTGAACTGGGGAGCCTGTTGAGACAAGATTTCCAAGG	3300
Qy	3327	ATTGCATAATGAATTATTGCTGCGTATTGGAGAACACTATCAACAGGTTTTTAATGGTTT	3386
Db	3301	ATTGCATAATGAATTATTGCTGCGTATTGGAGAACACTATCAACAGGTTTTTAATGGTTT	3360
Qy	3387	GTCAATACTTGCCTCATTTGCATCCAGTGATGATCCATATCAGGGCCCGAGAGATATCAT	3446
Db	3361	GTCAATACTTGCCTCATTTGCATCCAGTGATGATCCATATCAGGGCCCGAGAGATATCAT	3420
Qy	3447	ATCACCTGAACTGATGGCTGATTATTTACAACCCAAATTGTTGGGCATTTTGGCTTTTTT	3506
Db	3421	ATCACCTGAACTGATGGCTGATTATTTACAACCCAAATTGTTGGGCATTTTGGCTTTTTT	3480
Qy	3507	TAACATGCAGTTACTGAGCTCTAGTGTTGGCATTGAAGATAAGAAAATGGCCTTGAACAG	3566
Db	3481	TAACATGCAGTTACTGAGCTCTAGTGTTGGCATTGAAGATAAGAAAATGGCCTTGAACAG	3540
Qy	3567	TTTGATGTCTTTGATGAAGTTAATGGGACCCAAACATGTCAAGTTCTGTGAGGGTGAAGAT	3626
Db	3541	TTTGATGTCTTTGATGAAGTTAATGGGACCCAAACATGTCAAGTTCTGTGAGGGTGAAGAT	3600
Qy	3627	GATGACCACACTGAGAACTGGCCTTCGATTCAAGGATGATTTTCCTGAATTGTGTTGCAG	3686
Db	3601	GATGACCACACTGAGAACTGGCCTTCGATTCAAGGATGATTTTCCTGAATTGTGTTGCAG	3660
Qy	3687	AGCTTGGGACTGCTTTGTTGCTGCCTGGATCATGCTTGTCTGGGCTCCCTTCTCAGTCA	3746
Db	3661	AGCTTGGGACTGCTTTGTTGCTGCCTGGATCATGCTTGTCTGGGCTCCCTTCTCAGTCA	3720
Qy	3747	TGTAATAGTAGCTTTGTTACCTCTTATACACATCCAGCCTAAAGAACTGCAGCTATCTT	3806
Db	3721	TGTAATAGTAGCTTTGTTACCTCTTATACACATCCAGCCTAAAGAACTGCAGCTATCTT	3780
Qy	3807	CCACTACCTCATAATTGAAAACAGGGATGCTGTGCAAGATTTTCTTCATGAAATATATTT	3866
Db	3781	CCACTACCTCATAATTGAAAACAGGGATGCTGTGCAAGATTTTCTTCATGAAATATATTT	3840
Qy	3867	TTTACCTGATCATCCAGAATTAAAAAGATAAAAGCCGTTCTCCAGGAATACAGAAAGGA	3926
Db	3841	TTTACCTGATCATCCAGAATTAAAAAGATAAAAGCCGTTCTCCAGGAATACAGAAAGGA	3900
Qy	3927	GACCTCTGAGAGCACTGATCTTCAGACAACCTCTTCAGCTCTCTATGAAGGCCATTCAACA	3986
Db	3901	GACCTCTGAGAGCACTGATCTTCAGACAACCTCTTCAGCTCTCTATGAAGGCCATTCAACA	3960
Qy	3987	TGAAAATGTCGATGTTTCGTATTATGCTCTTACAAGCTTGAAGGAAACCTTGTATAAAAA	4046
Db	3961	TGAAAATGTCGATGTTTCGTATTATGCTCTTACAAGCTTGAAGGAAACCTTGTATAAAAA	4020
Qy	4047	TCAGGAAAAACTGATAAAGTATGCAACAGACAGTGAACAGTAGAACCTATTATCTCACA	4106
Db	4021	TCAGGAAAAACTGATAAAGTATGCAACAGACAGTGAACAGTAGAACCTATTATCTCACA	4080
Qy	4107	GTTGGTGACAGTGCTTTTGAAAGGTTGCCAAGATGCAAACCTCTCAAGCTCGGTTGCTCTG	4166
Db	4081	GTTGGTGACAGTGCTTTTGAAAGGTTGCCAAGATGCAAACCTCTCAAGCTCGGTTGCTCTG	4140

Qy	4167	TGGGGAATGTTTAGGGGAATTGGGGGCGATAGATCCAGGTCGATTAGATTCTCAACAAC	4226
Db	4141	TGGGGAATGTTTAGGGGAATTGGGGGCGATAGATCCAGGTCGATTAGATTCTCAACAAC	4200
Qy	4227	TGAAACTCAAGGAAAAGATTTTACATTTGTGACTGGAGTAGAAGATTCAAGCTTTCCTA	4286
Db	4201	TGAAACTCAAGGAAAAGATTTTACATTTGTGACTGGAGTAGAAGATTCAAGCTTTCCTA	4260
Qy	4287	TGGATTATTGATGGAGCTAACAAGAGCTTACCTTGCCTATGCTGATAATAGCCGAGCTCA	4346
Db	4261	TGGATTATTGATGGAGCTAACAAGAGCTTACCTTGCCTATGCTGATAATAGCCGAGCTCA	4320
Qy	4347	AGATTCAGCTGCCTATGCCATTGAGGAGTTGCTTTCTATTTATGACTGTAGAGAGATGGA	4406
Db	4321	AGATTCAGCTGCCTATGCCATTGAGGAGTTGCTTTCTATTTATGACTGTAGAGAGATGGA	4380
Qy	4407	GACCAACGGCCAGGTACCAATTGTGGAGGAGATTTCCTGAGCATGTTGGGAAATACT	4466
Db	4381	GACCAACGGCCAGGTACCAATTGTGGAGGAGATTTCCTGAGCATGTTGGGAAATACT	4440
Qy	4467	AGAACCTCATCTAAATACCAGATACAAGAGTTCTCAGAAGTCAACCGATTGGTCTGGAGT	4526
Db	4441	AGAACCTCATCTAAATACCAGATACAAGAGTTCTCAGAAGTCAACCGATTGGTCTGGAGT	4500
Qy	4527	AAAGAAGCCAATTTACTTAAGTAAATTGGGTAGTAACCTTGCAGAATGGTCAGCATCTTG	4586
Db	4501	AAAGAAGCCAATTTACTTAAGTAAATTGGGTAGTAACCTTGCAGAATGGTCAGCATCTTG	4560
Qy	4587	GGCAGGTTATCTTATTACAAAGGTTTCGACATGATCTTGCCAGTAAAATTTTACCTGCTG	4646
Db	4561	GGCAGGTTATCTTATTACAAAGGTTTCGACATGATCTTGCCAGTAAAATTTTACCTGCTG	4620
Qy	4647	TAGCATTATGATGAAGCATGATTTCAAAGTGACCATCTATCTTCTCCACATATTCTGGT	4706
Db	4621	TAGCATTATGATGAAGCATGATTTCAAAGTGACCATCTATCTTCTCCACATATTCTGGT	4680
Qy	4707	GTATGTCTTACTGGGTTGTAATCAAGAAGATCAGCAGGAGTTTATGCAGAAATTATGGC	4766
Db	4681	GTATGTCTTACTGGGTTGTAATCAAGAAGATCAGCAGGAGTTTATGCAGAAATTATGGC	4740
Qy	4767	AGTTCTAAAGCATGACGATCAGCATACCATAAATACCCAAGACATTGCATCTGATCTGTG	4826
Db	4741	AGTTCTAAAGCATGACGATCAGCATACCATAAATACCCAAGACATTGCATCTGATCTGTG	4800
Qy	4827	TCAACTCAGTACACAGACTGTGTTCTCCATGCTTGACCATCTCACACAGTGGGCAAGGCA	4886
Db	4801	TCAACTCAGTACACAGACTGTGTTCTCCATGCTTGACCATCTCACACAGTGGGCAAGGCA	4860
Qy	4887	CAAATTTACAGGCACTGAAAGCTGAGAAATGTCCACACAGCAAATCAAACAGAAATAAGGT	4946
Db	4861	CAAATTTACAGGCACTGAAAGCTGAGAAATGTCCACACAGCAAATCAAACAGAAATAAGGT	4920
Qy	4947	AGACTCAATGGTATCTACTGTGGATTATGAAGACTATCAGAGTGTAAACCGTTTCTAGA	5006
Db	4921	AGACTCAATGGTATCTACTGTGGATTATGAAGACTATCAGAGTGTAAACCGTTTCTAGA	4980
Qy	5007	CCTCATACCCAGGATACTCTGGCAGTAGCTTCCTTTGCTCCAAAGCATACACACGAGC	5066
Db	4981	CCTCATACCCAGGATACTCTGGCAGTAGCTTCCTTTGCTCCAAAGCATACACACGAGC	5040
Qy	5067	TGTAATGCACTTTGAATCATTTATTACAGAAAAGAAGCAAATATTAGGAACATCTTGG	5126
Db	5041	TGTAATGCACTTTGAATCATTTATTACAGAAAAGAAGCAAATATTAGGAACATCTTGG	5100
Qy	5127	ATTTTACAGAAATTGTATGCTGCTATGCATGAACCTGATGGAGTGGCCGGAGTCAGTGC	5186
Db	5101	ATTTTACAGAAATTGTATGCTGCTATGCATGAACCTGATGGAGTGGCCGGAGTCAGTGC	5160
Qy	5187	AATTAGAAAGGCAGAACCATTCTCTAAAAGAACAGATCCTTGAACATGAAAGCCTTGGCTT	5246
Db	5161	AATTAGAAAGGCAGAACCATTCTCTAAAAGAACAGATCCTTGAACATGAAAGCCTTGGCTT	5220
Qy	5247	GCTGAGGGATGCCACTGCTTGTATGACAGGGCTATTCAGCTAGAACCAGACCAGATCAT	5306
Db	5221	GCTGAGGGATGCCACTGCTTGTATGACAGGGCTATTCAGCTAGAACCAGACCAGATCAT	5280

Qy	5307	TCATTATCATGGTGTAGTAAAGTCCATGTTAGGTCTTGGTCAGCTGTCTACTGTTATCAC	5366
Db	5281	TCATTATCATGGTGTAGTAAAGTCCATGTTAGGTCTTGGTCAGCTGTCTACTGTTATCAC	5340
Qy	5367	TCAGGTGAATGGAGTGCATGCTAACAGGTCCGAGTGGACAGATGAATTAACACGTACAG	5426
Db	5341	TCAGGTGAATGGAGTGCATGCTAACAGGTCCGAGTGGACAGATGAATTAACACGTACAG	5400
Qy	5427	AGTGAAGCAGCTTGAAATTGTCACAGTGGGATTTGGTGGAAACTATTTGGCAGCAGA	5486
Db	5401	AGTGAAGCAGCTTGAAATTGTCACAGTGGGATTTGGTGGAAACTATTTGGCAGCAGA	5460
Qy	5487	TGGAAATCTACAACATGGAGTGTGAGACTGGGACAGCTATTATTATCAGCCAAAAAAG	5546
Db	5461	TGGAAATCTACAACATGGAGTGTGAGACTGGGACAGCTATTATTATCAGCCAAAAAAG	5520
Qy	5547	AGATATCACAGCTTTTATGACTCACTGAACTAGTGAGAGCAGAACAAATTGTACCTCT	5606
Db	5521	AGATATCACAGCTTTTATGACTCACTGAACTAGTGAGAGCAGAACAAATTGTACCTCT	5580
Qy	5607	TTCAGCTGCAAGCTTTGAAAGAGGCTCCTACCAACGAGGATATGAATATATTGTGAGATT	5666
Db	5581	TTCAGCTGCAAGCTTTGAAAGAGGCTCCTACCAACGAGGATATGAATATATTGTGAGATT	5640
Qy	5667	GCACATGTTATGTGAGTTGGAGCATAGCATCAAACCACTTTTCCAGCATTCTCCAGGTGA	5726
Db	5641	GCACATGTTATGTGAGTTGGAGCATAGCATCAAACCACTTTTCCAGCATTCTCCAGGTGA	5700
Qy	5727	CAGTTCTCAAGAAGATTCTCTAACTGGGTAGCTCGACTAGAAATGACCCAGAATTCCTA	5786
Db	5701	CAGTTCTCAAGAAGATTCTCTAACTGGGTAGCTCGACTAGAAATGACCCAGAATTCCTA	5760
Qy	5787	CAGAGCCAAGGAGCCTATCCTGGCTCTCCGAGGGCTTTACTAAGCCTCAACAAAAGACC	5846
Db	5761	CAGAGCCAAGGAGCCTATCCTGGCTCTCCGAGGGCTTTACTAAGCCTCAACAAAAGACC	5820
Qy	5847	AGATTACAATGAAATGGTTGGAGAATGCTGGCTGCAGAGTGCCAGGGTAGCTAGAAAGGC	5906
Db	5821	AGATTACAATGAAATGGTTGGAGAATGCTGGCTGCAGAGTGCCAGGGTAGCTAGAAAGGC	5880
Qy	5907	TGGTCACCACCAGACAGCCTACAATGCTCTCCTTAATGCAGGGGAATCACGACTCGCTGA	5966
Db	5881	TGGTCACCACCAGACAGCCTACAATGCTCTCCTTAATGCAGGGGAATCACGACTCGCTGA	5940
Qy	5967	ACTGTACGTGGAAGGGCAAAGTGGCTCTGGTCCAAGGGTGATGTTCAACAGGCCTAAT	6026
Db	5941	ACTGTACGTGGAAGGGCAAAGTGGCTCTGGTCCAAGGGTGATGTTCAACAGGCCTAAT	6000
Qy	6027	TGTTCTTCAAAAAGGTGTTGAATTATGTTTTCCTGAAAATGAAACCCACCTGAGGGTAA	6086
Db	6001	TGTTCTTCAAAAAGGTGTTGAATTATGTTTTCCTGAAAATGAAACCCACCTGAGGGTAA	6060
Qy	6087	GAACATGTTAATCCATGGTCGAGCTATGCTACTAGTGGGCCGATTTATGGAAGAAACAGC	6146
Db	6061	GAACATGTTAATCCATGGTCGAGCTATGCTACTAGTGGGCCGATTTATGGAAGAAACAGC	6120
Qy	6147	TAACCTTTGAAAGCAATGCAATTATGAAAAAATATAAGGATGTGACCGCGTGCCTGCCAGA	6206
Db	6121	TAACCTTTGAAAGCAATGCAATTATGAAAAAATATAAGGATGTGACCGCGTGCCTGCCAGA	6180
Qy	6207	ATGGGAGGATGGGCATTTTACCTTGCCAAGTACTATGACAAATTGATGCCCATGGTCAC	6266
Db	6181	ATGGGAGGATGGGCATTTTACCTTGCCAAGTACTATGACAAATTGATGCCCATGGTCAC	6240
Qy	6267	AGACAACAAAATGGAAAAGCAAGGTGATCTCATCCGGTATATAGTTCTTCATTTTGGCAG	6326
Db	6241	AGACAACAAAATGGAAAAGCAAGGTGATCTCATCCGGTATATAGTTCTTCATTTTGGCAG	6300
Qy	6327	ATCTCTACAATATGGAAATCAGTTCATATATCAGTCAATGCCACGAATGTTAACTCTATG	6386
Db	6301	ATCTCTACAATATGGAAATCAGTTCATATATCAGTCAATGCCACGAATGTTAACTCTATG	6360
Qy	6387	GCTTGATTATGGTACAAAGGCATATGAATGGGAAAAAGCTGGCCGCTCCGATCGTGTACA	6446
Db	6361	GCTTGATTATGGTACAAAGGCATATGAATGGGAAAAAGCTGGCCGCTCCGATCGTGTACA	6420

Qy	6447	AATGAGGAATGATTTGGGTAAAATAAACAAAGGTTATCACAGAGCATACAACTATTTAGC	6506
Db	6421	AATGAGGAATGATTTGGGTAAAATAAACAAAGGTTATCACAGAGCATACAACTATTTAGC	6480
Qy	6507	TCCATATCAATTTTTGACTGCTTTTTACAATTGATCTCTCGAATTTGTCATTCTCACGA	6566
Db	6481	TCCATATCAATTTTTGACTGCTTTTTACAATTGATCTCTCGAATTTGTCATTCTCACGA	6540
Qy	6567	TGAAGTTTTTGTGCTTGATGGAATAATAGCCAAAGTATTTCTAGCCTATCCTCAACA	6626
Db	6541	TGAAGTTTTTGTGCTTGATGGAATAATAGCCAAAGTATTTCTAGCCTATCCTCAACA	6600
Qy	6627	AGCAATGTGGATGATGACAGCTGTGTCAAAGTCATCTTATCCCATGCGTGTGAACAGATG	6686
Db	6601	AGCAATGTGGATGATGACAGCTGTGTCAAAGTCATCTTATCCCATGCGTGTGAACAGATG	6660
Qy	6687	CAAGGAAATCCTCAATAAAGCTATTCATATGAAAAATCCTTAGAGAAGTTTGTGGAGA	6746
Db	6661	CAAGGAAATCCTCAATAAAGCTATTCATATGAAAAATCCTTAGAGAAGTTTGTGGAGA	6720
Qy	6747	TGCAACTCGCCTAACAGATAAGCTTCTAGAATTGTGCAATAAACCGGTTGATGGAAGTAG	6806
Db	6721	TGCAACTCGCCTAACAGATAAGCTTCTAGAATTGTGCAATAAACCGGTTGATGGAAGTAG	6780
Qy	6807	TTCCACATTAAGCATGAGCACTCATTTTAAATGCTTAAAAAGCTGGTAGAAGAAGCAAC	6866
Db	6781	TTCCACATTAAGCATGAGCACTCATTTTAAATGCTTAAAAAGCTGGTAGAAGAAGCAAC	6840
Qy	6867	ATTTAGTGAAATCCTCATTCCTCTACAATCAGTCATGATACCTACACTTCCATCAATTCT	6926
Db	6841	ATTTAGTGAAATCCTCATTCCTCTACAATCAGTCATGATACCTACACTTCCATCAATTCT	6900
Qy	6927	GGGTACCCATGCTAACCATGCTAGCCATGAACCATTTCCTGGACATTGGGCCTATATTGC	6986
Db	6901	GGGTACCCATGCTAACCATGCTAGCCATGAACCATTTCCTGGACATTGGGCCTATATTGC	6960
Qy	6987	AGGGTTTGATGATATGGTGGAAATTCCTGCTTCTCTTCAGAAACCAAAGAAGATTCTTT	7046
Db	6961	AGGGTTTGATGATATGGTGGAAATTCCTGCTTCTCTTCAGAAACCAAAGAAGATTCTTT	7020
Qy	7047	AAAAGGCTCAGATGGAAAGTTCTACATCATGATGTGTAAGCCAAAAGATGACCTGAGAAA	7106
Db	7021	AAAAGGCTCAGATGGAAAGTTCTACATCATGATGTGTAAGCCAAAAGATGACCTGAGAAA	7080
Qy	7107	GGATTGTAGACTAATGGAATTCATTCCCTTGATTAATAAGTGCTTAAGAAAAGATGCAGA	7166
Db	7081	GGATTGTAGACTAATGGAATTCATTCCCTTGATTAATAAGTGCTTAAGAAAAGATGCAGA	7140
Qy	7167	GTCTCGTAGAAGAGAACTTCATATTCGAACATATGCAGTTATTCCACTAAATGATGAATG	7226
Db	7141	GTCTCGTAGAAGAGAACTTCATATTCGAACATATGCAGTTATTCCACTAAATGATGAATG	7200
Qy	7227	TGGGATTATTGAATGGGTGAACAACACTGCTGGTTTGAGACCTATTCTGACCAAATATA	7286
Db	7201	TGGGATTATTGAATGGGTGAACAACACTGCTGGTTTGAGACCTATTCTGACCAAATATA	7260
Qy	7287	TAAAGAAAAGGGAGTGTATATGACAGGAAAAGAACTTCGCCAGTGTATGCTACCAAAGTC	7346
Db	7261	TAAAGAAAAGGGAGTGTATATGACAGGAAAAGAACTTCGCCAGTGTATGCTACCAAAGTC	7320
Qy	7347	AGCAGCTTTATCTGAAAACTCAAAGTATTCGAGAATTTCTCCTGCCAGGCATCCTCC	7406
Db	7321	AGCAGCTTTATCTGAAAACTCAAAGTATTCGAGAATTTCTCCTGCCAGGCATCCTCC	7380
Qy	7407	TATTTTTCATGAGTGGTTTCTGAGAACATTCCCTGATCCTACATCATGGTACAGTAGTAG	7466
Db	7381	TATTTTTCATGAGTGGTTTCTGAGAACATTCCCTGATCCTACATCATGGTACAGTAGTAG	7440
Qy	7467	ATCAGCTTACTGCCGTTCCACTGCAGTAATGTCAATGGTTGGTTATATTCTGGGGCTTGG	7526
Db	7441	ATCAGCTTACTGCCGTTCCACTGCAGTAATGTCAATGGTTGGTTATATTCTGGGGCTTGG	7500
Qy	7527	AGACCGTCATGGTGAAAAATATTCTCTTTGATTCTTTGACTGGTGAATGCGTACATGTAGA	7586
Db	7501	AGACCGTCATGGTGAAAAATATTCTCTTTGATTCTTTGACTGGTGAATGCGTACATGTAGA	7560


```
Qy      7587 TTTCAATTGTCTTTTCAATAAGGGAGAAACCTTTGAAGTTCAGAAATTGTGCCATTTTCG 7646
        |||
Db      7561 TTTCAATTGTCTTTTCAATAAGGGAGAAACCTTTGAAGTTCAGAAATTGTGCCATTTTCG 7620

Qy      7647 CCTGACTCATAATATGGTTAATGGAATGGGTCCTATGGGAACAGAGGGTCTTTTTCGAAG 7706
        |||
Db      7621 CCTGACTCATAATATGGTTAATGGAATGGGTCCTATGGGAACAGAGGGTCTTTTTCGAAG 7680

Qy      7707 AGCATGTGAAGTTACAATGAGGCTGATGCGTGATCAGCGAGAGCCTTTAATGAGTGTCTT 7766
        |||
Db      7681 AGCATGTGAAGTTACAATGAGGCTGATGCGTGATCAGCGAGAGCCTTTAATGAGTGTCTT 7740

Qy      7767 AAAGACTTTTCTACATGATCCTCTTGTGGAATGGAGTAAACCAGTGAAAGGGCATTCCAA 7826
        |||
Db      7741 AAAGACTTTTCTACATGATCCTCTTGTGGAATGGAGTAAACCAGTGAAAGGGCATTCCAA 7800

Qy      7827 AGCGCCACTGAATGAACTGGAGAAGTTGTCAATGAAAAGGCCAAGACCCATGTTCTTGA 7886
        |||
Db      7801 AGCGCCACTGAATGAACTGGAGAAGTTGTCAATGAAAAGGCCAAGACCCATGTTCTTGA 7860

Qy      7887 CATTGAGCAGCGACTACAAGGTGTAATCAAGACTCGAAATAGAGTGACAGGACTGCCGTT 7946
        |||
Db      7861 CATTGAGCAGCGACTACAAGGTGTAATCAAGACTCGAAATAGAGTGACAGGACTGCCGTT 7920

Qy      7947 ATCTATTGAAGGACATGTGCATTACCTTATACAAGAAGCTACTGATGAAAACCTACTATG 8006
        |||
Db      7921 ATCTATTGAAGGACATGTGCATTACCTTATACAAGAAGCTACTGATGAAAACCTACTATG 7980

Qy      8007 CCAGATGTATCTTGGTTGGACTCCATATATGTGAAATGAAATTATGTAAAAGAATATGTT 8066
        |||
Db      7981 CCAGATGTATCTTGGTTGGACTCCATATATGTGAAATGAAATTATGTAAAAGAATATGTT 8040

Qy      8067 AATAATCTAAAAGTAATGCATTTGGTATGAATCTGTGGTTGTATCTGTTCAATTCTAAAG 8126
        |||
Db      8041 AATAATCTAAAAGTAATGCATTTGGTATGAATCTGTGGTTGTATCTGTTCAATTCTAAAG 8100

Qy      8127 TACAACATAAATTTACGTTCTCAGCAACTGTTATTTCTCTCTGATCATTAAATTATATGTA 8186
        |||
Db      8101 TACAACATAAATTTACGTTCTCAGCAACTGTTATTTCTCTCTGATCATTAAATTATATGTA 8160

Qy      8187 AAATAATATACATTAGTTATTAAGAAATAAACTGCTTTCTTAATAAAAAAAAAAAAAAAAA 8246
        |||
Db      8161 AAATAATATACATTAGTTATTAAGAAATAAACTGCTTTCTTAATAAAAAAAAAAAAAAAAA 8220

Qy      8247 AAAAAAAAAAAAAAAAAAAAAA 8265
        |||
Db      8221 AAAAAAAAAAAAAAAAAAAAAA 8239
<!--EndFragment-->
```

Exhibit C

<!--StartFragment-->RESULT 01

US-10-300-453B-38

; Sequence 38, Application US/10300453B

; Patent No. 7101985

; GENERAL INFORMATION:

; APPLICANT: ELLEDGE, STEPHEN J.

; APPLICANT: CORTEZ, DAVID K.

; APPLICANT: ZOU, LEE

; TITLE OF INVENTION: METHODS AND COMPOSITIONS IN CHECKPOINT SIGNALING

; FILE REFERENCE: P02339US1

; CURRENT APPLICATION NUMBER: US/10/300,453B

; CURRENT FILING DATE: 2002-11-20

; PRIOR APPLICATION NUMBER: 60/331,821

; PRIOR FILING DATE: 2001-11-20

; NUMBER OF SEQ ID NOS: 50

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 38

; LENGTH: 8265

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-300-453B-38

Query Match 100.0%; Score 8265; DB 5; Length 8265;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 8265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 GCCTCCACACGGCTCCGTCGGGCGCCGCGCTCTTCCGGCAGCGGTACGTTTGGAGACGCC 60
        |||
Db      1 GCCTCCACACGGCTCCGTCGGGCGCCGCGCTCTTCCGGCAGCGGTACGTTTGGAGACGCC 60

Qy     61 GGGAAACCCGCGTTGGCGTGGTTGACTAGTGCCTCGCAGCCTCAGCATGGGGGAACATGGC 120
        |||
Db     61 GGGAAACCCGCGTTGGCGTGGTTGACTAGTGCCTCGCAGCCTCAGCATGGGGGAACATGGC 120

Qy    121 CTGGAGCTGGCTTCCATGATCCCCGCCCTGCGGGAGCTGGGCAGTGCCACACCAGAGGAA 180
        |||
Db    121 CTGGAGCTGGCTTCCATGATCCCCGCCCTGCGGGAGCTGGGCAGTGCCACACCAGAGGAA 180

Qy    181 TATAATACAGTTGTACAGAAGCCAAGACAAATTCTGTGTCAATTATTGACCGGATACTT 240
        |||
Db    181 TATAATACAGTTGTACAGAAGCCAAGACAAATTCTGTGTCAATTATTGACCGGATACTT 240

Qy    241 ACAGATGTAAATGTTGTTGCTGTAGAACTTGTAAAGAAAAGTACTCTCAGCCACCTCC 300
        |||
Db    241 ACAGATGTAAATGTTGTTGCTGTAGAACTTGTAAAGAAAAGTACTCTCAGCCACCTCC 300

Qy    301 GTGATGTTGCTTGATTTTCATCCAGCATATCATGAAATCCTCCCCACTTATGTTTGTAAAT 360
        |||
Db    301 GTGATGTTGCTTGATTTTCATCCAGCATATCATGAAATCCTCCCCACTTATGTTTGTAAAT 360

Qy    361 GTGAGTGGAAGCCATGAGCGCAAAGGCAGTTGTATTGAATTGAGTAATTGGATCATAACG 420
        |||
Db    361 GTGAGTGGAAGCCATGAGCGCAAAGGCAGTTGTATTGAATTGAGTAATTGGATCATAACG 420

Qy    421 AGACTTCTGCGGATTGCAGCAACTCCCTCCTGTCAATTTGTTACACAAGAAAATCTGTGAA 480
        |||
Db    421 AGACTTCTGCGGATTGCAGCAACTCCCTCCTGTCAATTTGTTACACAAGAAAATCTGTGAA 480

Qy    481 GTCATCTGTTTATTATTATTTCTTTTAAAGCAAGAGTCCTGCTATTTTGGGGTACTC 540
        |||
Db    481 GTCATCTGTTTATTATTATTTCTTTTAAAGCAAGAGTCCTGCTATTTTGGGGTACTC 540

Qy    541 ACAAAGAATTATTACAACCTTTTGAAGACTTGGTTTACCTCCATAGAAGAAATGTGATG 600
        |||
Db    541 ACAAAGAATTATTACAACCTTTTGAAGACTTGGTTTACCTCCATAGAAGAAATGTGATG 600

Qy    601 GGTCACTGCTGTGGAATGGCCAGTGGTCATGAGCCGATTTTAAAGTCAATTAGATGAACAC 660
        |||
Db    601 GGTCACTGCTGTGGAATGGCCAGTGGTCATGAGCCGATTTTAAAGTCAATTAGATGAACAC 660

Qy    661 ATGGGATATTTACAATCAGCTCCTTTGCAGTTGATGAGTATGCAAAATTTAGAATTTATT 720
        |||
Db    661 ATGGGATATTTACAATCAGCTCCTTTGCAGTTGATGAGTATGCAAAATTTAGAATTTATT 720

Qy    721 GAAGTCACTTTATTAATGGTTCTTACTCGTATTATTGCAATTGTGTTTTTAGAAGGCAA 780
        |||

```

Db	721	GAAGTCACTTTATTAATGGTTCTTACTCGTATTATTGCAATTGTGTTTTTAGAAGGCAA	780
Qy	781	GAAGTCACTTTATTAATGGTTCTTACTCGTATTATTGCAATTGTGTTTTTAGAAGGCAA	840
Db	781	GAAGTCACTTTATTAATGGTTCTTACTCGTATTATTGCAATTGTGTTTTTAGAAGGCAA	840
Qy	841	TCCCTAGCAATTAGCTTTTAAACAGAACTTTTTCAGCTTGGAGGACTACCAGCACAACCA	900
Db	841	TCCCTAGCAATTAGCTTTTAAACAGAACTTTTTCAGCTTGGAGGACTACCAGCACAACCA	900
Qy	901	GCTAGCACTTTTTTCAGCTCATTTTTGAATTATTAAACACCTTGTAGAAATGGATACT	960
Db	901	GCTAGCACTTTTTTCAGCTCATTTTTGAATTATTAAACACCTTGTAGAAATGGATACT	960
Qy	961	GACCAATTGAAACTCTATGAAGAGCCATTATCAAAGCTGATAAAGACACTATTTCCCTTT	1020
Db	961	GACCAATTGAAACTCTATGAAGAGCCATTATCAAAGCTGATAAAGACACTATTTCCCTTT	1020
Qy	1021	GAAGCAGAAGCTTATAGAAATATTGAACCTGTCTATTAAATATGCTGCTGGAAAACTC	1080
Db	1021	GAAGCAGAAGCTTATAGAAATATTGAACCTGTCTATTAAATATGCTGCTGGAAAACTC	1080
Qy	1081	TGTGTCATGTTTGAAGACGGTGTGCTCATGCGGCTTAAGTCTGATTGCTAAAAGCAGCT	1140
Db	1081	TGTGTCATGTTTGAAGACGGTGTGCTCATGCGGCTTAAGTCTGATTGCTAAAAGCAGCT	1140
Qy	1141	TTGTGCCATTTACTGCAGTATTTCCCTTAAATTTGTGCCAGCTGGGTATGAATCTGCTTTA	1200
Db	1141	TTGTGCCATTTACTGCAGTATTTCCCTTAAATTTGTGCCAGCTGGGTATGAATCTGCTTTA	1200
Qy	1201	CAAGTCAGGAAGGTCTATGTGAGAAATATTTGTAAAGCTCTTTTGGATGTGCTTGGAAAT	1260
Db	1201	CAAGTCAGGAAGGTCTATGTGAGAAATATTTGTAAAGCTCTTTTGGATGTGCTTGGAAAT	1260
Qy	1261	GAGGTAGATGCAGAGTACTTGTGGGCCCACTTTATGCAGCTTTGAAATGGAAAGTATG	1320
Db	1261	GAGGTAGATGCAGAGTACTTGTGGGCCCACTTTATGCAGCTTTGAAATGGAAAGTATG	1320
Qy	1321	GAAATCATTGAGGAGATTCAATGCCAACTCAACAGGAAAACCTCAGCAGTAATAGTGAT	1380
Db	1321	GAAATCATTGAGGAGATTCAATGCCAACTCAACAGGAAAACCTCAGCAGTAATAGTGAT	1380
Qy	1381	GGAATATCACCCAAAAGGCGTCGTCTCAGCTCGTCTCTAAACCTTCTAAAAGAGCACCA	1440
Db	1381	GGAATATCACCCAAAAGGCGTCGTCTCAGCTCGTCTCTAAACCTTCTAAAAGAGCACCA	1440
Qy	1441	AAACAGACTGAGGAAATTAAACATGTGGACATGAACCAAAGAGCATATTATGGAGTGCA	1500
Db	1441	AAACAGACTGAGGAAATTAAACATGTGGACATGAACCAAAGAGCATATTATGGAGTGCA	1500
Qy	1501	CTGAAACAGAAAGCTGAATCCCTTCAGATTTCCCTTGAATACAGTGGCCTAAAGAATCCT	1560
Db	1501	CTGAAACAGAAAGCTGAATCCCTTCAGATTTCCCTTGAATACAGTGGCCTAAAGAATCCT	1560
Qy	1561	GTTATTGAGATGTTAGAAGGAATTGCTGTTGTCTTACAACCTGACTGCTCTGTGACTGTT	1620
Db	1561	GTTATTGAGATGTTAGAAGGAATTGCTGTTGTCTTACAACCTGACTGCTCTGTGACTGTT	1620
Qy	1621	CATTGTTCTCATCAAACATGAAGTCCGTAATTTCAAGGACTGTCAACATAAATCCAAG	1680
Db	1621	CATTGTTCTCATCAAACATGAAGTCCGTAATTTCAAGGACTGTCAACATAAATCCAAG	1680
Qy	1681	AAGAAACCTTCTGTAGTGATAAATTGGATGTCATTGGATTTTACACAAAAGTGCTTAAG	1740
Db	1681	AAGAAACCTTCTGTAGTGATAAATTGGATGTCATTGGATTTTACACAAAAGTGCTTAAG	1740
Qy	1741	AGCTGTAGAAGTTTGTGTAAGTCTGTTTCAAGAACTGGACCTGGAGGCAACCATTTGATAAG	1800
Db	1741	AGCTGTAGAAGTTTGTGTAAGTCTGTTTCAAGAACTGGACCTGGAGGCAACCATTTGATAAG	1800
Qy	1801	GTGGTGAAAATTTATGATGCTTTGATTTATATGCAAGTAAACAGTTCATTTGAAGATCAT	1860
Db	1801	GTGGTGAAAATTTATGATGCTTTGATTTATATGCAAGTAAACAGTTCATTTGAAGATCAT	1860
Qy	1861	ATCCTGGAAGATTTATGTGGTATGCTCTCACTTCCATGGATTTATTTCCATTCTGATGAT	1920

Db	1861	ATCCTGGAAGATTATGTGGTATGCTCTCACTTCCATGGATTATTCCCATTCTGATGAT	1920
Qy	1921	GGCTGTTTAAAGTTGACCACATTGGCCGCTAATCTTCTAACATTAAGCTGTAGGATTTCA	1980
Db	1921	GGCTGTTTAAAGTTGACCACATTGGCCGCTAATCTTCTAACATTAAGCTGTAGGATTTCA	1980
Qy	1981	GATAGCTATTACCACAGGCACAATCACGATGTGTGTTTCTTCTGACTCTGTTTCCAAGA	2040
Db	1981	GATAGCTATTACCACAGGCACAATCACGATGTGTGTTTCTTCTGACTCTGTTTCCAAGA	2040
Qy	2041	AGAATATTCTTGAGTGGAGAACAGCAGTTTACAACCTGGGCCCTGCAGAGCTCCCATGAA	2100
Db	2041	AGAATATTCTTGAGTGGAGAACAGCAGTTTACAACCTGGGCCCTGCAGAGCTCCCATGAA	2100
Qy	2101	GTAATCCGGGCTAGTTGTGTAGTGGATTTTTATCTTATTGCAGCAGCAGAATTCTTGT	2160
Db	2101	GTAATCCGGGCTAGTTGTGTAGTGGATTTTTATCTTATTGCAGCAGCAGAATTCTTGT	2160
Qy	2161	AACAGAGTTCCTCAAGATTCTTATAGATAAAGTCAAAGATGATTCTGACATTGTCAAGAAA	2220
Db	2161	AACAGAGTTCCTCAAGATTCTTATAGATAAAGTCAAAGATGATTCTGACATTGTCAAGAAA	2220
Qy	2221	GAATTTGCTTCTATACTTGGTCAACTTGCTGTACTCTTACGGCATGTTTATCTGACA	2280
Db	2221	GAATTTGCTTCTATACTTGGTCAACTTGCTGTACTCTTACGGCATGTTTATCTGACA	2280
Qy	2281	AGTTCTTTAACAGAACCTTTCTCTGAACACGGACATGTGGACCTCTTCTGTAGGAACCTTG	2340
Db	2281	AGTTCTTTAACAGAACCTTTCTCTGAACACGGACATGTGGACCTCTTCTGTAGGAACCTTG	2340
Qy	2341	AAAGCCACTTCTCAACATGAATGTTTCATCTTCTCAACTAAAAGCTTCTGTCTGCAAGCCA	2400
Db	2341	AAAGCCACTTCTCAACATGAATGTTTCATCTTCTCAACTAAAAGCTTCTGTCTGCAAGCCA	2400
Qy	2401	TTCTTTTCTACTGAAAAAAAATACCTAGTCCAGTAAAACCTTGCTTTCATAGATAAT	2460
Db	2401	TTCTTTTCTACTGAAAAAAAATACCTAGTCCAGTAAAACCTTGCTTTCATAGATAAT	2460
Qy	2461	CTACATCATCTTTGTAAGCATCTTGATTTTAGAGAAGATGAAACAGATGTAAGAGCAGTT	2520
Db	2461	CTACATCATCTTTGTAAGCATCTTGATTTTAGAGAAGATGAAACAGATGTAAGAGCAGTT	2520
Qy	2521	CTTGGAACCTTTATTAATTTAATGGAAGATCCAGACAAAGATGTTAGAGTGGCTTTTAGT	2580
Db	2521	CTTGGAACCTTTATTAATTTAATGGAAGATCCAGACAAAGATGTTAGAGTGGCTTTTAGT	2580
Qy	2581	GGAATATCAAGCACATATTGGAATCCTTGGACTCTGAAGATGGATTTATAAGGAGCTT	2640
Db	2581	GGAATATCAAGCACATATTGGAATCCTTGGACTCTGAAGATGGATTTATAAGGAGCTT	2640
Qy	2641	TTTGTCTTAAGAATGAAGGAAGCATATACACATGCCCAAATATCAAGAAATAATGAGCTG	2700
Db	2641	TTTGTCTTAAGAATGAAGGAAGCATATACACATGCCCAAATATCAAGAAATAATGAGCTG	2700
Qy	2701	AAGGATACCTTGATTCTTACAACAGGGGATATTGGAAGGGCCGCAAAGGAGATTGGTA	2760
Db	2701	AAGGATACCTTGATTCTTACAACAGGGGATATTGGAAGGGCCGCAAAGGAGATTGGTA	2760
Qy	2761	CCATTTGCACTCTTACACTTATTGCATTGTTTGTATCCAAGTCAGCATCTGTCTCTGGA	2820
Db	2761	CCATTTGCACTCTTACACTTATTGCATTGTTTGTATCCAAGTCAGCATCTGTCTCTGGA	2820
Qy	2821	GCAGCATACAGAAATTAGAGCTCTGGTTGCAGCTAAAAGTGTTAACTGCAAAGTTT	2880
Db	2821	GCAGCATACAGAAATTAGAGCTCTGGTTGCAGCTAAAAGTGTTAACTGCAAAGTTT	2880
Qy	2881	TTGAGCCAGTATAAGAAACCCATCTGTGAGTTTGGTAGAATCCCTTCACTCTAGTCAG	2940
Db	2881	TTGAGCCAGTATAAGAAACCCATCTGTGAGTTTGGTAGAATCCCTTCACTCTAGTCAG	2940
Qy	2941	ATGACAGCACTTCCGAATACTCCATGCCAGAATGCTGACGTGCGAAAACAAGATGTGGCT	3000
Db	2941	ATGACAGCACTTCCGAATACTCCATGCCAGAATGCTGACGTGCGAAAACAAGATGTGGCT	3000
Qy	3001	CACCAGAGAGAAATGGCTTTAAATACGTTGTCTGAATTGCCAACGTTTTCGACTTTCCT	3060

Db	3001	CACCAGAGAGAAATGGCTTTAAATACGTTGTCTGAAATTGCCAACGTTTTCGACTTTCCT	3060
Qy	3061	GATCTTAATCGTTTTCTTACTAGGACATTACAAGTTCTACTACCTGATCTTGCTGCCAAA	3120
Db	3061	GATCTTAATCGTTTTCTTACTAGGACATTACAAGTTCTACTACCTGATCTTGCTGCCAAA	3120
Qy	3121	GCAAGCCCTGCAGCTTCTGCTCTCATTTCGAACCTTAGGAAAACAATTAAATGTCAATCGT	3180
Db	3121	GCAAGCCCTGCAGCTTCTGCTCTCATTTCGAACCTTAGGAAAACAATTAAATGTCAATCGT	3180
Qy	3181	AGAGAGATTTTAATAAAACAACCTTCAAATATATTTTTCTCATTGGTCTGTTCTTGTTCC	3240
Db	3181	AGAGAGATTTTAATAAAACAACCTTCAAATATATTTTTCTCATTGGTCTGTTCTTGTTCC	3240
Qy	3241	AAAGATGAATTAGAACGTGCCCTTCATTATCTGAAGAATGAAACAGAAATTGAACTGGGG	3300
Db	3241	AAAGATGAATTAGAACGTGCCCTTCATTATCTGAAGAATGAAACAGAAATTGAACTGGGG	3300
Qy	3301	AGCCTGTTGAGACAAGATTTCCAAGGATTGCATAATGAATTATTGCTGCGTATTGGAGAA	3360
Db	3301	AGCCTGTTGAGACAAGATTTCCAAGGATTGCATAATGAATTATTGCTGCGTATTGGAGAA	3360
Qy	3361	CACATCAACAGGTTTTTAATGGTTTGTCAATACTTGCCTCATTTGCATCCAGTGATGAT	3420
Db	3361	CACATCAACAGGTTTTTAATGGTTTGTCAATACTTGCCTCATTTGCATCCAGTGATGAT	3420
Qy	3421	CCATATCAGGGCCCAGAGATATCATATCACCTGAACTGATGGCTGATTATTTACAACCC	3480
Db	3421	CCATATCAGGGCCCAGAGATATCATATCACCTGAACTGATGGCTGATTATTTACAACCC	3480
Qy	3481	AAATTGTTGGGCATTTTGGCTTTTTTAACATGCAGTTACTGAGCTCTAGTGTGGCATT	3540
Db	3481	AAATTGTTGGGCATTTTGGCTTTTTTAACATGCAGTTACTGAGCTCTAGTGTGGCATT	3540
Qy	3541	GAAGATAAGAAAATGGCCTTGAACAGTTTGATGTCTTTGATGAAGTTAATGGGACCCAAA	3600
Db	3541	GAAGATAAGAAAATGGCCTTGAACAGTTTGATGTCTTTGATGAAGTTAATGGGACCCAAA	3600
Qy	3601	CATGTCAGTTCTGTGAGGGTGAAGATGATGACCACACTGAGAACTGGCCTTCGATTCAAG	3660
Db	3601	CATGTCAGTTCTGTGAGGGTGAAGATGATGACCACACTGAGAACTGGCCTTCGATTCAAG	3660
Qy	3661	GATGATTTTCTGAATTGTGTTGCAGAGCTTGGGACTGCTTTGTTTCGCTGCCTGGATCAT	3720
Db	3661	GATGATTTTCTGAATTGTGTTGCAGAGCTTGGGACTGCTTTGTTTCGCTGCCTGGATCAT	3720
Qy	3721	GCTTGTCTGGGCTCCCTTCTCAGTCATGTAATAGTAGCTTTGTTACCTCTTATACACATC	3780
Db	3721	GCTTGTCTGGGCTCCCTTCTCAGTCATGTAATAGTAGCTTTGTTACCTCTTATACACATC	3780
Qy	3781	CAGCCTAAAGAACTGCAGCTATCTTCCACTACCTCATAATTGAAAACAGGGATGCTGTG	3840
Db	3781	CAGCCTAAAGAACTGCAGCTATCTTCCACTACCTCATAATTGAAAACAGGGATGCTGTG	3840
Qy	3841	CAAGATTTTCTTCATGAAATATATTTTTTACCTGATCATCCAGAATTAAAAAGATAAAA	3900
Db	3841	CAAGATTTTCTTCATGAAATATATTTTTTACCTGATCATCCAGAATTAAAAAGATAAAA	3900
Qy	3901	GCCGTTCTCCAGGAATACAGAAAGGAGACCTCTGAGAGCACTGATCTTCAGACAACCTTT	3960
Db	3901	GCCGTTCTCCAGGAATACAGAAAGGAGACCTCTGAGAGCACTGATCTTCAGACAACCTTT	3960
Qy	3961	CAGCTCTCTATGAAGGCCATTCAACATGAAAATGTCGATGTTGCTATTTCATGCTCTTACA	4020
Db	3961	CAGCTCTCTATGAAGGCCATTCAACATGAAAATGTCGATGTTGCTATTTCATGCTCTTACA	4020
Qy	4021	AGCTTGAAGGAAACCTTGATAAAAAATCAGGAAAAACTGATAAAGTATGCAACAGACAGT	4080
Db	4021	AGCTTGAAGGAAACCTTGATAAAAAATCAGGAAAAACTGATAAAGTATGCAACAGACAGT	4080
Qy	4081	GAAACAGTAGAACCTATTATCTCACAGTTGGTGACAGTGCTTTTGAAAGGTTGCCAAGAT	4140
Db	4081	GAAACAGTAGAACCTATTATCTCACAGTTGGTGACAGTGCTTTTGAAAGGTTGCCAAGAT	4140
Qy	4141	GCAAACTCTCAAGCTCGGTTGCTCTGTGGGGAATGTTAGGGGAATTGGGGGCGATAGAT	4200

Db	4141	GCAAACCTCTCAAGCTCGGTTGCTCTGTGGGAATGTTTAGGGGAATTGGGGGCGATAGAT	4200
Qy	4201	CCAGGTCGATTAGATTTCTCAACAACCTGAACTCAAGGAAAAGATTTACATTTGTGACT	4260
Db	4201	CCAGGTCGATTAGATTTCTCAACAACCTGAACTCAAGGAAAAGATTTACATTTGTGACT	4260
Qy	4261	GGAGTAGAAGATTCAAGCTTTGCCTATGGATTATTGATGGAGCTAACAAGAGCTTACCTT	4320
Db	4261	GGAGTAGAAGATTCAAGCTTTGCCTATGGATTATTGATGGAGCTAACAAGAGCTTACCTT	4320
Qy	4321	GCGTATGCTGATAATAGCCGAGCTCAAGATTCAAGCTGCCTATGCCATTCAAGAGTTGCTT	4380
Db	4321	GCGTATGCTGATAATAGCCGAGCTCAAGATTCAAGCTGCCTATGCCATTCAAGAGTTGCTT	4380
Qy	4381	TCTATTTATGACTGTAGAGAGATGGAGACCAACGGCCAGGTCACCAATTGTGGAGGAGA	4440
Db	4381	TCTATTTATGACTGTAGAGAGATGGAGACCAACGGCCAGGTCACCAATTGTGGAGGAGA	4440
Qy	4441	TTTCCTGAGCATGTTGCGGAAATACTAGAACCTCATCTAAATACCAGATACAAGAGTTCT	4500
Db	4441	TTTCCTGAGCATGTTGCGGAAATACTAGAACCTCATCTAAATACCAGATACAAGAGTTCT	4500
Qy	4501	CAGAAGTCAACCGATTGGTCTGGAGTAAGAAGCCAATTTACTTAAGTAAATTGGGTAGT	4560
Db	4501	CAGAAGTCAACCGATTGGTCTGGAGTAAGAAGCCAATTTACTTAAGTAAATTGGGTAGT	4560
Qy	4561	AACTTTGCGAATGGTCAGCATCTTGGGCAGGTTATCTTATTACAAAGGTTGACATGAT	4620
Db	4561	AACTTTGCGAATGGTCAGCATCTTGGGCAGGTTATCTTATTACAAAGGTTGACATGAT	4620
Qy	4621	CTTGCCAGTAAAATTTTACCTGCTGTAGCATTATGATGAAGCATGATTTCAAAGTGACC	4680
Db	4621	CTTGCCAGTAAAATTTTACCTGCTGTAGCATTATGATGAAGCATGATTTCAAAGTGACC	4680
Qy	4681	ATCTATCTTCTTCCACATATTCTGGTGTATGTCTTACTGGGTTGTAATCAAGAAGATCAG	4740
Db	4681	ATCTATCTTCTTCCACATATTCTGGTGTATGTCTTACTGGGTTGTAATCAAGAAGATCAG	4740
Qy	4741	CAGGAGGTTTATGCAGAAATTATGGCAGTTCTAAAGCATGACGATCAGCATACCATAAAT	4800
Db	4741	CAGGAGGTTTATGCAGAAATTATGGCAGTTCTAAAGCATGACGATCAGCATACCATAAAT	4800
Qy	4801	ACCCAAGACATTGCATCTGATCTGTGTCAACTCAGTACACAGACTGTGTTCTCCATGCTT	4860
Db	4801	ACCCAAGACATTGCATCTGATCTGTGTCAACTCAGTACACAGACTGTGTTCTCCATGCTT	4860
Qy	4861	GACCATCTCACACAGTGGCAAGGCACAAATTTAGGCACTGAAAGCTGAGAAATGTCCA	4920
Db	4861	GACCATCTCACACAGTGGCAAGGCACAAATTTAGGCACTGAAAGCTGAGAAATGTCCA	4920
Qy	4921	CACAGCAAATCAACAGAAATAAGGTAGACTCAATGGTATCTACTGTGGATTATGAAGAC	4980
Db	4921	CACAGCAAATCAACAGAAATAAGGTAGACTCAATGGTATCTACTGTGGATTATGAAGAC	4980
Qy	4981	TATCAGAGTGTAACCCGTTTCTAGACCTCATACCCAGGATACTCTGGCAGTAGCTTCC	5040
Db	4981	TATCAGAGTGTAACCCGTTTCTAGACCTCATACCCAGGATACTCTGGCAGTAGCTTCC	5040
Qy	5041	TTTCGCTCCAAGCATACACACGAGCTGTAATGCACTTGAATCATTTATTACAGAAAAG	5100
Db	5041	TTTCGCTCCAAGCATACACACGAGCTGTAATGCACTTGAATCATTTATTACAGAAAAG	5100
Qy	5101	AAGCAAAATATTACAGGAACATCTTGATTTTACAGAAATTGTATGCTGCTATGCATGAA	5160
Db	5101	AAGCAAAATATTACAGGAACATCTTGATTTTACAGAAATTGTATGCTGCTATGCATGAA	5160
Qy	5161	CCTGATGGAGTGGCCGGAGTCAGTGCAATTAGAAAGGCAGAACCATCTCTAAAAGAACAG	5220
Db	5161	CCTGATGGAGTGGCCGGAGTCAGTGCAATTAGAAAGGCAGAACCATCTCTAAAAGAACAG	5220
Qy	5221	ATCCTTGAACATGAAAGCCTTGCTTGTGAGGGATGCCACTGCTTGTTATGACAGGGCT	5280
Db	5221	ATCCTTGAACATGAAAGCCTTGCTTGTGAGGGATGCCACTGCTTGTTATGACAGGGCT	5280
Qy	5281	ATTGAGCTAGAACCAGACCAGATCATTCAATATCATGGTGTAGTAAAGTCCATGTTAGGT	5340

Db	5281	ATTGAGCTAGAACCCAGACCAGATCATTCATTATCATGGTGTAGTAAAGTCCATGTTAGGT	5340
Qy	5341	CTTGGTCAGCTGTCTACTGTTATCACTCAGGTGAATGGAGTGCATGCTAACAGGTCCGAG	5400
Db	5341	CTTGGTCAGCTGTCTACTGTTATCACTCAGGTGAATGGAGTGCATGCTAACAGGTCCGAG	5400
Qy	5401	TGGACAGATGAATTAACACGTACAGAGTGAAGCAGCTTGGAAATTGTCACAGTGGGAT	5460
Db	5401	TGGACAGATGAATTAACACGTACAGAGTGAAGCAGCTTGGAAATTGTCACAGTGGGAT	5460
Qy	5461	TTGGTGGAAAACCTATTTGGCAGCAGATGGAAAATCTACAACATGGAGTGTGAGACTGGGA	5520
Db	5461	TTGGTGGAAAACCTATTTGGCAGCAGATGGAAAATCTACAACATGGAGTGTGAGACTGGGA	5520
Qy	5521	CAGCTATTATTATCAGCCAAAAAAGAGATATCACAGCTTTTATGACTCACTGAAACTA	5580
Db	5521	CAGCTATTATTATCAGCCAAAAAAGAGATATCACAGCTTTTATGACTCACTGAAACTA	5580
Qy	5581	GTGAGAGCAGAACAAATTGTACCTCTTTCAGCTGCAAGCTTTGAAAGAGGCTCCTACCAA	5640
Db	5581	GTGAGAGCAGAACAAATTGTACCTCTTTCAGCTGCAAGCTTTGAAAGAGGCTCCTACCAA	5640
Qy	5641	CGAGGATATGAATATATTGTGAGATTGCACATGTTATGTGAGTTGGAGCATAGCATCAAA	5700
Db	5641	CGAGGATATGAATATATTGTGAGATTGCACATGTTATGTGAGTTGGAGCATAGCATCAAA	5700
Qy	5701	CCACTTTTCCAGCATTCTCCAGGTGACAGTTCTCAAGAAGATTCTCTAAACTGGGTAGCT	5760
Db	5701	CCACTTTTCCAGCATTCTCCAGGTGACAGTTCTCAAGAAGATTCTCTAAACTGGGTAGCT	5760
Qy	5761	CGACTAGAAATGACCCAGAATTCTACAGAGCCAAGGAGCCTATCCTGGCTCTCCGGAGG	5820
Db	5761	CGACTAGAAATGACCCAGAATTCTACAGAGCCAAGGAGCCTATCCTGGCTCTCCGGAGG	5820
Qy	5821	GCTTTACTAAGCCTCAACAAAAGACCAGATTACAATGAAATGGTTGGAGAATGCTGGCTG	5880
Db	5821	GCTTTACTAAGCCTCAACAAAAGACCAGATTACAATGAAATGGTTGGAGAATGCTGGCTG	5880
Qy	5881	CAGAGTGCCAGGGTAGCTAGAAAGGCTGGTCACCACCAGACAGCCTACAATGCTCTCCTT	5940
Db	5881	CAGAGTGCCAGGGTAGCTAGAAAGGCTGGTCACCACCAGACAGCCTACAATGCTCTCCTT	5940
Qy	5941	AATGCAGGGGAATCAGACTCGCTGAACTGTACGTGGAAGGGCAAAGTGGCTCTGGTCC	6000
Db	5941	AATGCAGGGGAATCAGACTCGCTGAACTGTACGTGGAAGGGCAAAGTGGCTCTGGTCC	6000
Qy	6001	AAGGGTGATGTTACCAGGCACTAATTGTTCTTCAAAAAGGTGTTGAATTATGTTTTCCT	6060
Db	6001	AAGGGTGATGTTACCAGGCACTAATTGTTCTTCAAAAAGGTGTTGAATTATGTTTTCCT	6060
Qy	6061	GAAATGAAACCCACCTGAGGGTAAGAACATGTTAATCCATGGTCGAGCTATGCTACTA	6120
Db	6061	GAAATGAAACCCACCTGAGGGTAAGAACATGTTAATCCATGGTCGAGCTATGCTACTA	6120
Qy	6121	GTGGGCCGATTTATGGAAGAAACAGCTAACTTTGAAAGCAATGCAATTATGAAAAATAT	6180
Db	6121	GTGGGCCGATTTATGGAAGAAACAGCTAACTTTGAAAGCAATGCAATTATGAAAAATAT	6180
Qy	6181	AAGGATGTGACCGCGTGCCTGCCAGAATGGGAGGATGGGCATTTTACCTTGCCAAGTAC	6240
Db	6181	AAGGATGTGACCGCGTGCCTGCCAGAATGGGAGGATGGGCATTTTACCTTGCCAAGTAC	6240
Qy	6241	TATGACAAATTGATGCCCATGGTCACAGACAACAAATGGAAAAGCAAGGTGATCTCATC	6300
Db	6241	TATGACAAATTGATGCCCATGGTCACAGACAACAAATGGAAAAGCAAGGTGATCTCATC	6300
Qy	6301	CGGTATATAGTTCTTCATTTTGGCAGATCTCTACAATATGGAAATCAGTTCATATATCAG	6360
Db	6301	CGGTATATAGTTCTTCATTTTGGCAGATCTCTACAATATGGAAATCAGTTCATATATCAG	6360
Qy	6361	TCAATGCCACGAATGTTAACTCTATGGCTTGATTATGGTACAAAGGCATATGAATGGGAA	6420
Db	6361	TCAATGCCACGAATGTTAACTCTATGGCTTGATTATGGTACAAAGGCATATGAATGGGAA	6420
Qy	6421	AAAGCTGGCCGCTCCGATCGGTACAAATGAGGAATGATTTGGGTAAAATAACAAGGTT	6480

Db 6421 AAAGCTGGCCGCTCCGATCGTGACAAATGAGGAATGATTTGGGTAAAATAAACAAGGTT 6480

Qy 6481 ATCACAGAGCATACAAACTATTTAGCTCCATATCAATTTTGGACTGCTTTTACAAATTG 6540
|||||

Db 6481 ATCACAGAGCATACAAACTATTTAGCTCCATATCAATTTTGGACTGCTTTTACAAATTG 6540

Qy 6541 ATCTCTCGAATTTGTCTTCTCAGCATGAAGTTTGTGTCTTGATGGAAATAATAGCC 6600
|||||

Db 6541 ATCTCTCGAATTTGTCTTCTCAGCATGAAGTTTGTGTCTTGATGGAAATAATAGCC 6600

Qy 6601 AAAGTATTTCTAGCCTATCCTCAACAAGCAATGTGGATGATGACAGCTGTGTCAAAGTCA 6660
|||||

Db 6601 AAAGTATTTCTAGCCTATCCTCAACAAGCAATGTGGATGATGACAGCTGTGTCAAAGTCA 6660

Qy 6661 TCTTATCCCATGCGTGTGAACAGATGCAAGGAAATCCTCAATAAGCTATTCATATGAAA 6720
|||||

Db 6661 TCTTATCCCATGCGTGTGAACAGATGCAAGGAAATCCTCAATAAGCTATTCATATGAAA 6720

Qy 6721 AAATCCTTAGAGAAGTTTGTGGAGATGCAACTCGCCTAACAGATAAGCTTCTAGAATTG 6780
|||||

Db 6721 AAATCCTTAGAGAAGTTTGTGGAGATGCAACTCGCCTAACAGATAAGCTTCTAGAATTG 6780

Qy 6781 TGCAATAAACCGGTTGATGGAAGTAGTTCCACATTAAGCATGAGCACTCATTTTAAATG 6840
|||||

Db 6781 TGCAATAAACCGGTTGATGGAAGTAGTTCCACATTAAGCATGAGCACTCATTTTAAATG 6840

Qy 6841 CTTAAAAAGCTGGTAGAAGAAGCAACATTTAGTGAAATCCTCATTCTCTACAATCAGTC 6900
|||||

Db 6841 CTTAAAAAGCTGGTAGAAGAAGCAACATTTAGTGAAATCCTCATTCTCTACAATCAGTC 6900

Qy 6901 ATGATACCTACACTTCCATCAATTCTGGGTACCCATGCTAACCATGCTAGCCATGAACCA 6960
|||||

Db 6901 ATGATACCTACACTTCCATCAATTCTGGGTACCCATGCTAACCATGCTAGCCATGAACCA 6960

Qy 6961 TTTCTGGACATTGGGCCTATATTGCAGGGTTTGATGATATGGTGGAAATCTTGCTTCT 7020
|||||

Db 6961 TTTCTGGACATTGGGCCTATATTGCAGGGTTTGATGATATGGTGGAAATCTTGCTTCT 7020

Qy 7021 CTTCAGAAACCAAAGAGATTTCTTTAAAAGGCTCAGATGGAAAGTTCTACATCATGATG 7080
|||||

Db 7021 CTTCAGAAACCAAAGAGATTTCTTTAAAAGGCTCAGATGGAAAGTTCTACATCATGATG 7080

Qy 7081 TGTAAGCCAAAAGATGACCTGAGAAAGGATTGTAGACTAATGGAATCAATTCCTTGATT 7140
|||||

Db 7081 TGTAAGCCAAAAGATGACCTGAGAAAGGATTGTAGACTAATGGAATCAATTCCTTGATT 7140

Qy 7141 AATAAGTGCTTAAGAAAAGATGCAGAGTCTCGTAGAAGAGAACTTCATATTCGAACATAT 7200
|||||

Db 7141 AATAAGTGCTTAAGAAAAGATGCAGAGTCTCGTAGAAGAGAACTTCATATTCGAACATAT 7200

Qy 7201 GCAGTTATTCCTACTAAATGATGAATGTGGGATTATTGAATGGGTGAACAACACTGCTGGT 7260
|||||

Db 7201 GCAGTTATTCCTACTAAATGATGAATGTGGGATTATTGAATGGGTGAACAACACTGCTGGT 7260

Qy 7261 TTGAGACCTATTCTGACCAAACCTATATAAGAAAAGGGAGTGTATATGACAGGAAAAGAA 7320
|||||

Db 7261 TTGAGACCTATTCTGACCAAACCTATATAAGAAAAGGGAGTGTATATGACAGGAAAAGAA 7320

Qy 7321 CTTGCCAGTGTATGCTACCAAAGTCAGCAGCTTTATCTGAAAACTCAAAGTATTCGA 7380
|||||

Db 7321 CTTGCCAGTGTATGCTACCAAAGTCAGCAGCTTTATCTGAAAACTCAAAGTATTCGA 7380

Qy 7381 GAATTTCTCCTGCCAGGCATCCTCCTATTTTTCATGAGTGGTTTCTGAGAACATTCCCT 7440
|||||

Db 7381 GAATTTCTCCTGCCAGGCATCCTCCTATTTTTCATGAGTGGTTTCTGAGAACATTCCCT 7440

Qy 7441 GATCCTACATCATGGTACAGTAGTAGATCAGCTTACTGCCGTTCCACTGCAGTAATGTCA 7500
|||||

Db 7441 GATCCTACATCATGGTACAGTAGTAGATCAGCTTACTGCCGTTCCACTGCAGTAATGTCA 7500

Qy 7501 ATGGTTGGTTATATTCTGGGGCTTGAGACCGTCATGGTGAAAATATTCTCTTTGATTCT 7560
|||||

Db 7501 ATGGTTGGTTATATTCTGGGGCTTGAGACCGTCATGGTGAAAATATTCTCTTTGATTCT 7560

Qy 7561 TTGACTGGTGAATGCGTACATGTAGATTTCATTTGTCTTTTCAATAAGGGAGAAACCTTT 7620
|||||


```
Db      7561 TTGACTGGTGAATGCGTACATGTAGATTCAATTGTCTTTCAATAAGGGAGAAACCTTT 7620
Qy      7621 GAAGTTCAGAAATTGTGCCATTTGCGCTGACTCATAATATGGTTAATGGAATGGGTCCT 7680
      |||
Db      7621 GAAGTTCAGAAATTGTGCCATTTGCGCTGACTCATAATATGGTTAATGGAATGGGTCCT 7680
Qy      7681 ATGGGAACAGAGGGTCTTTTTCGAAGAGCATGTGAAGTTACAATGAGGCTGATGCGTGAT 7740
      |||
Db      7681 ATGGGAACAGAGGGTCTTTTTCGAAGAGCATGTGAAGTTACAATGAGGCTGATGCGTGAT 7740
Qy      7741 CAGCGAGAGCCTTTAATGAGTGTCTTAAAGACTTTTCTACATGATCCTCTTGTTGGAATGG 7800
      |||
Db      7741 CAGCGAGAGCCTTTAATGAGTGTCTTAAAGACTTTTCTACATGATCCTCTTGTTGGAATGG 7800
Qy      7801 AGTAAACCAAGTGAAGGGCATTCCAAGCGCCACTGAATGAACTGGAGAAGTTGTCAAT 7860
      |||
Db      7801 AGTAAACCAAGTGAAGGGCATTCCAAGCGCCACTGAATGAACTGGAGAAGTTGTCAAT 7860
Qy      7861 GAAAAGGCCAAGACCCATGTTCTTGACATTGAGCAGCGACTACAAGGTGTAATCAAGACT 7920
      |||
Db      7861 GAAAAGGCCAAGACCCATGTTCTTGACATTGAGCAGCGACTACAAGGTGTAATCAAGACT 7920
Qy      7921 CGAAATAGAGTGACAGGACTGCCGTTATCTATTGAAGGACATGTGCATTACCTTATACAA 7980
      |||
Db      7921 CGAAATAGAGTGACAGGACTGCCGTTATCTATTGAAGGACATGTGCATTACCTTATACAA 7980
Qy      7981 GAAGCTACTGATGAAAACCTTACTATGCCAGATGTATCTTGGTTGGACTCCATATATGTGA 8040
      |||
Db      7981 GAAGCTACTGATGAAAACCTTACTATGCCAGATGTATCTTGGTTGGACTCCATATATGTGA 8040
Qy      8041 AATGAAATTATGTAAAAGAATATGTTAATAATCTAAAAGTAATGCATTGGTATGAATCT 8100
      |||
Db      8041 AATGAAATTATGTAAAAGAATATGTTAATAATCTAAAAGTAATGCATTGGTATGAATCT 8100
Qy      8101 GTGGTTGTATCTGTTCAATTCTAAAGTACAACATAAATTTACGTTCTCAGCAACTGTTAT 8160
      |||
Db      8101 GTGGTTGTATCTGTTCAATTCTAAAGTACAACATAAATTTACGTTCTCAGCAACTGTTAT 8160
Qy      8161 TTCTCTCTGATCATTAAATTATATGTAAAATAATATACATTGAGTTATTAAGAAATAAACT 8220
      |||
Db      8161 TTCTCTCTGATCATTAAATTATATGTAAAATAATATACATTGAGTTATTAAGAAATAAACT 8220
Qy      8221 GCTTTCTTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 8265
      |||
Db      8221 GCTTTCTTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 8265
```

<!--EndFragment-->

Exhibit D

```

<!--StartFragment-->RESULT 1
US-10-388-360-295
; Sequence 295, Application US/10388360
; Patent No. 7081340
; GENERAL INFORMATION:
; APPLICANT: GENOMIC HEALTH
; APPLICANT: Baker, Joffre B.
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Kiefer, Michael C.
; APPLICANT: Shak, Steve
; APPLICANT: Walker, Michael Graham
; TITLE OF INVENTION: GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES
; FILE REFERENCE: 39740-0001US
; CURRENT APPLICATION NUMBER: US/10/388,360
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/412,049
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: US 60/364,890
; PRIOR FILING DATE: 2002-03-13
; NUMBER OF SEQ ID NOS: 384
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 295
; LENGTH: 2042
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-388-360-295

```

```

Query Match          100.0%; Score 2042; DB 5; Length 2042;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2042; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 GGGGCCAGTCGTTGCGCCGAAAGCATTTGTCTCCACCTCATCATAACAACAATTAATTT 60
        |||
Db      1 GGGGCCAGTCGTTGCGCCGAAAGCATTTGTCTCCACCTCATCATAACAACAATTAATTT 60

Qy     61 CCTCTGGGCCTGAGGAGGGCAGAATTTCAACCTTCGGTGTGCTTGGGAGTGGCGATTGT 120
        |||
Db     61 CCTCTGGGCCTGAGGAGGGCAGAATTTCAACCTTCGGTGTGCTTGGGAGTGGCGATTGT 120

Qy    121 GATTTACACGACAAAATGCCGAGGTGCTCGGTGGAGTCATGGCAGTGCCCTTTGTGGAAG 180
        |||
Db    121 GATTTACACGACAAAATGCCGAGGTGCTCGGTGGAGTCATGGCAGTGCCCTTTGTGGAAG 180

Qy    181 ACTGGGACTTGGTGCAAACCTGGGAGAAGGTGCCTATGGAGAAGTTCAACTTGCTGTGA 240
        |||
Db    181 ACTGGGACTTGGTGCAAACCTGGGAGAAGGTGCCTATGGAGAAGTTCAACTTGCTGTGA 240

Qy    241 ATAGAGTAACTGAAGAAGCAGTCGCAGTGAAGATTGTAGATATGAAGCGTGCCGTAGACT 300
        |||
Db    241 ATAGAGTAACTGAAGAAGCAGTCGCAGTGAAGATTGTAGATATGAAGCGTGCCGTAGACT 300

Qy    301 GTCCAGAAAATATTAAGAAAGAGATCTGTATCAATAAAATGCTAAATCATGAAAATGTAG 360
        |||
Db    301 GTCCAGAAAATATTAAGAAAGAGATCTGTATCAATAAAATGCTAAATCATGAAAATGTAG 360

Qy    361 TAAAAATCTATGGTCACAGGAGAGAAGGCAATATCCAATATTTATTTCTGGAGTACTGTA 420
        |||
Db    361 TAAAAATCTATGGTCACAGGAGAGAAGGCAATATCCAATATTTATTTCTGGAGTACTGTA 420

Qy    421 GTGGAGGAGAGCTTTTTGACAGAATAGAGCCAGACATAGGCATGCCTGAACCAGATGCTC 480
        |||
Db    421 GTGGAGGAGAGCTTTTTGACAGAATAGAGCCAGACATAGGCATGCCTGAACCAGATGCTC 480

Qy    481 AGAGATTCTTCCATCAACTCATGGCAGGGGTGGTTTATCTGCATGGTATTGGAATAAATC 540
        |||
Db    481 AGAGATTCTTCCATCAACTCATGGCAGGGGTGGTTTATCTGCATGGTATTGGAATAAATC 540

Qy    541 ACAGGGATATTAACCCAGAAAATCTTCTGTTGGATGAAAGGGATAACCTCAAAATCTCAG 600
        |||
Db    541 ACAGGGATATTAACCCAGAAAATCTTCTGTTGGATGAAAGGGATAACCTCAAAATCTCAG 600

Qy    601 ACTTTGGCTTGGCAACAGTATTTCCGGTATAATAATCGTGAGCGTTTGTGAACAAGATGT 660
        |||
Db    601 ACTTTGGCTTGGCAACAGTATTTCCGGTATAATAATCGTGAGCGTTTGTGAACAAGATGT 660

Qy    661 GTGGTACTTTACCATATGTTGCTCCAGAACTTCTGAAGAGAAGAGAATTTATGCAGAAC 720

```

```

Db      661  |||||
GTGGTACTTTACCATATGTTGCTCCAGAACTTCTGAAGAGAAGAGAATTTTCATGCAGAAC 720

Qy      721  CAGTTGATGTTTGGTCCTGTGGAATAGTACTTACTGCAATGCTCGCTGGAGAATTGCCAT 780
|||||

Db      721  CAGTTGATGTTTGGTCCTGTGGAATAGTACTTACTGCAATGCTCGCTGGAGAATTGCCAT 780
|||||

Qy      781  GGGACCAACCCAGTGACAGCTGTCAGGAGTATTCTGACTGGAAAGAAAAAACATACC 840
|||||

Db      781  GGGACCAACCCAGTGACAGCTGTCAGGAGTATTCTGACTGGAAAGAAAAAACATACC 840
|||||

Qy      841  TCAACCCCTTGAAAAAAATCGATTCTGCTCCTCTAGCTCTGCTGCATAAAATCTTAGTTG 900
|||||

Db      841  TCAACCCCTTGAAAAAAATCGATTCTGCTCCTCTAGCTCTGCTGCATAAAATCTTAGTTG 900
|||||

Qy      901  AGAATCCATCAGCAAGAATTACCATTCCAGACATCAAAAAGATAGATGGTACAACAAAC 960
|||||

Db      901  AGAATCCATCAGCAAGAATTACCATTCCAGACATCAAAAAGATAGATGGTACAACAAAC 960
|||||

Qy      961  CCCTCAAGAAAGGGGCAAAAAGGCCCGAGTCACTTCAGGTGGTGTGTGAGAGTCTCCCA 1020
|||||

Db      961  CCCTCAAGAAAGGGGCAAAAAGGCCCGAGTCACTTCAGGTGGTGTGTGAGAGTCTCCCA 1020
|||||

Qy      1021 GTGGATTTTCTAAGCACATTCAATCCAATTTGGACTTCTCTCCAGTAAACAGTGCTTCTA 1080
|||||

Db      1021 GTGGATTTTCTAAGCACATTCAATCCAATTTGGACTTCTCTCCAGTAAACAGTGCTTCTA 1080
|||||

Qy      1081 GTGAAGAAAATGTGAAGTACTCCAGTTCTCAGCCAGAACCCCGCACAGGTCTTTCCTTAT 1140
|||||

Db      1081 GTGAAGAAAATGTGAAGTACTCCAGTTCTCAGCCAGAACCCCGCACAGGTCTTTCCTTAT 1140
|||||

Qy      1141 GGGATACCAGCCCCTCATACATTGATAAATTGGTACAAGGGATCAGCTTTTCCAGCCCA 1200
|||||

Db      1141 GGGATACCAGCCCCTCATACATTGATAAATTGGTACAAGGGATCAGCTTTTCCAGCCCA 1200
|||||

Qy      1201 CATGTCCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCCAGGATCCTCACAGA 1260
|||||

Db      1201 CATGTCCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCCAGGATCCTCACAGA 1260
|||||

Qy      1261 ACCCCTGGCAGCGGTTGGTCAAAGAATGACACGATTCTTTACCAAATTGGATGCAGACA 1320
|||||

Db      1261 ACCCCTGGCAGCGGTTGGTCAAAGAATGACACGATTCTTTACCAAATTGGATGCAGACA 1320
|||||

Qy      1321 AATCTTATCAATGCCTGAAAGAGACTTGTGAGAAGTTGGGCTATCAATGGAAGAAAAGTT 1380
|||||

Db      1321 AATCTTATCAATGCCTGAAAGAGACTTGTGAGAAGTTGGGCTATCAATGGAAGAAAAGTT 1380
|||||

Qy      1381 GTATGAATCAGGTTACTATATCAACAACTGATAGGAGAAACAATAAATCAATTTCAAAG 1440
|||||

Db      1381 GTATGAATCAGGTTACTATATCAACAACTGATAGGAGAAACAATAAATCAATTTCAAAG 1440
|||||

Qy      1441 TGAATTTGTTAGAAATGGATGATAAAATATTGGTTGACTTCCGGCTTTCTAAGGGTGATG 1500
|||||

Db      1441 TGAATTTGTTAGAAATGGATGATAAAATATTGGTTGACTTCCGGCTTTCTAAGGGTGATG 1500
|||||

Qy      1501 GATTGGAGTTCAAGAGACACTTCCTGAAGATTAAAGGGAAGCTGATTGATATTGTGAGCA 1560
|||||

Db      1501 GATTGGAGTTCAAGAGACACTTCCTGAAGATTAAAGGGAAGCTGATTGATATTGTGAGCA 1560
|||||

Qy      1561 GCCAGAAGGTTTGGCTTCCTGCCACATGATCGGACCATCGGCTCTGGGGAATCCTGGTGA 1620
|||||

Db      1561 GCCAGAAGGTTTGGCTTCCTGCCACATGATCGGACCATCGGCTCTGGGGAATCCTGGTGA 1620
|||||

Qy      1621 ATATAGTGCTGCTATGTTGACATTATTCTTCCTAGAGAAGATTATCCTGTCTGCAAACT 1680
|||||

Db      1621 ATATAGTGCTGCTATGTTGACATTATTCTTCCTAGAGAAGATTATCCTGTCTGCAAACT 1680
|||||

Qy      1681 GCAAATAGTAGTTTCTGAAGTGTTCACTTCCCTGTTTATCCAAACATCTTCCAATTTATT 1740
|||||

Db      1681 GCAAATAGTAGTTTCTGAAGTGTTCACTTCCCTGTTTATCCAAACATCTTCCAATTTATT 1740
|||||

Qy      1741 TTGTTTGTTCGGCATACAAATAATACCTATATCTTAATTGTAAGCAAACTTTGGGGAAA 1800
|||||

Db      1741 TTGTTTGTTCGGCATACAAATAATACCTATATCTTAATTGTAAGCAAACTTTGGGGAAA 1800
|||||

Qy      1801 GGATGAATAGAATTCAATTTGATTATTTCTTCATGTGTGTTTAGTATCTGAATTTGAACT 1860

```

```

Db      1801  GGATGAATAGAATTCATTTGATTATTTCTTCATGTGTGTTTAGTATCTGAATTTGAAACT 1860
Qy      1861  CATCTGGTGGAAACCAAGTTTCAGGGGACATGAGTTTCCAGCTTTTATACACACGTATC 1920
Db      1861  CATCTGGTGGAAACCAAGTTTCAGGGGACATGAGTTTCCAGCTTTTATACACACGTATC 1920
Qy      1921  TCATTTTATCAAAACATTTTGTTTAATTCAAAAAGTACATATTTCTTCCATGTTGATTT 1980
Db      1921  TCATTTTATCAAAACATTTTGTTTAATTCAAAAAGTACATATTTCTTCCATGTTGATTT 1980
Qy      1981  AATTCTAAGATGAACCAATAAAGACATAATTCTTGCAAAAAAAAAAAAAAAAAAAAAA 2040
Db      1981  AATTCTAAGATGAACCAATAAAGACATAATTCTTGCAAAAAAAAAAAAAAAAAAAAAA 2040
Qy      2041  AA 2042
Db      2041  AA 2042
```

<!--EndFragment-->